ES2758841T3 - Moduladores heterocíclicos selectivos del receptor de la esfingosina-1-fosfato - Google Patents
Moduladores heterocíclicos selectivos del receptor de la esfingosina-1-fosfato Download PDFInfo
- Publication number
- ES2758841T3 ES2758841T3 ES12785231T ES12785231T ES2758841T3 ES 2758841 T3 ES2758841 T3 ES 2758841T3 ES 12785231 T ES12785231 T ES 12785231T ES 12785231 T ES12785231 T ES 12785231T ES 2758841 T3 ES2758841 T3 ES 2758841T3
- Authority
- ES
- Spain
- Prior art keywords
- dihydro
- compound
- indene
- cyano
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 125000000623 heterocyclic group Chemical group 0.000 title description 30
- 229940127530 Sphingosine 1-Phosphate Receptor Modulators Drugs 0.000 title description 2
- -1 di-substituted phenyl Chemical group 0.000 claims abstract description 405
- 150000001875 compounds Chemical class 0.000 claims abstract description 363
- 150000003839 salts Chemical class 0.000 claims abstract description 55
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims abstract description 42
- 239000000651 prodrug Substances 0.000 claims abstract description 32
- 229940002612 prodrug Drugs 0.000 claims abstract description 32
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 29
- 150000002148 esters Chemical class 0.000 claims abstract description 25
- 125000004076 pyridyl group Chemical group 0.000 claims abstract description 23
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 19
- 125000003277 amino group Chemical group 0.000 claims abstract description 18
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims abstract description 17
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 17
- 125000002887 hydroxy group Chemical class [H]O* 0.000 claims abstract description 16
- 125000002971 oxazolyl group Chemical group 0.000 claims abstract description 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 15
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 10
- 150000001413 amino acids Chemical class 0.000 claims abstract description 9
- 125000001475 halogen functional group Chemical group 0.000 claims abstract description 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 8
- 125000005912 ethyl carbonate group Chemical class 0.000 claims abstract description 4
- DWLVWMUCHSLGSU-UHFFFAOYSA-M n,n-dimethylcarbamate Chemical compound CN(C)C([O-])=O DWLVWMUCHSLGSU-UHFFFAOYSA-M 0.000 claims abstract description 4
- 229950010765 pivalate Drugs 0.000 claims abstract description 4
- 150000003862 amino acid derivatives Chemical class 0.000 claims abstract description 3
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 claims abstract 2
- 125000000217 alkyl group Chemical group 0.000 claims description 88
- 229910052799 carbon Inorganic materials 0.000 claims description 62
- 125000003545 alkoxy group Chemical group 0.000 claims description 25
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 claims description 21
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 claims description 21
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 20
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 20
- 239000012453 solvate Substances 0.000 claims description 20
- 238000011282 treatment Methods 0.000 claims description 20
- 230000004913 activation Effects 0.000 claims description 19
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 19
- 229910052739 hydrogen Inorganic materials 0.000 claims description 15
- 201000006417 multiple sclerosis Diseases 0.000 claims description 14
- 230000008484 agonism Effects 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 206010052779 Transplant rejections Diseases 0.000 claims description 9
- 230000001154 acute effect Effects 0.000 claims description 9
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 7
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 7
- 206010022000 influenza Diseases 0.000 claims description 7
- 208000011231 Crohn disease Diseases 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 206010038687 Respiratory distress Diseases 0.000 claims 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract description 10
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 323
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 237
- 238000000034 method Methods 0.000 description 221
- 239000000243 solution Substances 0.000 description 182
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 156
- 239000011541 reaction mixture Substances 0.000 description 148
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 139
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 128
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 116
- 239000000203 mixture Substances 0.000 description 115
- 239000007787 solid Substances 0.000 description 99
- 238000006243 chemical reaction Methods 0.000 description 88
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 85
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 74
- 238000002953 preparative HPLC Methods 0.000 description 68
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 63
- 239000002904 solvent Substances 0.000 description 63
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 60
- 238000005481 NMR spectroscopy Methods 0.000 description 60
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 59
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 58
- 229940000406 drug candidate Drugs 0.000 description 54
- 102000005962 receptors Human genes 0.000 description 53
- 108020003175 receptors Proteins 0.000 description 53
- 238000005160 1H NMR spectroscopy Methods 0.000 description 48
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 48
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 48
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 44
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 43
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 42
- 239000012267 brine Substances 0.000 description 42
- 238000002360 preparation method Methods 0.000 description 39
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 38
- 239000000556 agonist Substances 0.000 description 36
- 238000000746 purification Methods 0.000 description 36
- 239000000047 product Substances 0.000 description 35
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 34
- 239000012044 organic layer Substances 0.000 description 34
- 125000005842 heteroatom Chemical group 0.000 description 33
- 125000003118 aryl group Chemical group 0.000 description 32
- 150000001412 amines Chemical class 0.000 description 31
- 239000000725 suspension Substances 0.000 description 31
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 30
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 30
- 238000004587 chromatography analysis Methods 0.000 description 30
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 29
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 27
- 238000003756 stirring Methods 0.000 description 27
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 26
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 26
- RUZLIIJDZBWWSA-INIZCTEOSA-N methyl 2-[[(1s)-1-(7-methyl-2-morpholin-4-yl-4-oxopyrido[1,2-a]pyrimidin-9-yl)ethyl]amino]benzoate Chemical group COC(=O)C1=CC=CC=C1N[C@@H](C)C1=CC(C)=CN2C(=O)C=C(N3CCOCC3)N=C12 RUZLIIJDZBWWSA-INIZCTEOSA-N 0.000 description 26
- 239000012043 crude product Substances 0.000 description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 25
- 238000007792 addition Methods 0.000 description 24
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 23
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 23
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 22
- 238000001816 cooling Methods 0.000 description 22
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 22
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 22
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical group C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 22
- 125000000753 cycloalkyl group Chemical group 0.000 description 21
- 101100348848 Mus musculus Notch4 gene Proteins 0.000 description 20
- 230000015572 biosynthetic process Effects 0.000 description 20
- 125000004432 carbon atom Chemical group C* 0.000 description 20
- 239000012069 chiral reagent Substances 0.000 description 20
- 239000000741 silica gel Substances 0.000 description 20
- 229910002027 silica gel Inorganic materials 0.000 description 20
- 238000003786 synthesis reaction Methods 0.000 description 20
- 101000767160 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Intracellular protein transport protein USO1 Proteins 0.000 description 19
- 239000002253 acid Substances 0.000 description 19
- 239000003153 chemical reaction reagent Substances 0.000 description 19
- 239000011734 sodium Substances 0.000 description 19
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- 239000000460 chlorine Substances 0.000 description 18
- 125000004043 oxo group Chemical group O=* 0.000 description 18
- 239000003981 vehicle Substances 0.000 description 18
- 239000012071 phase Substances 0.000 description 17
- SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 description 16
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 16
- OUBORTRIKPEZMG-UHFFFAOYSA-N INT-2 Chemical compound Nc1c(ncn1-c1ccc(F)cc1)C(=N)C#N OUBORTRIKPEZMG-UHFFFAOYSA-N 0.000 description 15
- 101001060278 Xenopus laevis Fibroblast growth factor 3 Proteins 0.000 description 15
- 238000004440 column chromatography Methods 0.000 description 15
- 125000001072 heteroaryl group Chemical group 0.000 description 15
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 15
- 229920006395 saturated elastomer Polymers 0.000 description 15
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 14
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 14
- 101100317378 Mus musculus Wnt3 gene Proteins 0.000 description 14
- 208000006673 asthma Diseases 0.000 description 14
- 238000004296 chiral HPLC Methods 0.000 description 14
- 208000035475 disorder Diseases 0.000 description 14
- 125000005843 halogen group Chemical group 0.000 description 14
- 229910052760 oxygen Inorganic materials 0.000 description 14
- 231100001274 therapeutic index Toxicity 0.000 description 14
- 229910052801 chlorine Inorganic materials 0.000 description 13
- 239000003446 ligand Substances 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 125000001424 substituent group Chemical group 0.000 description 13
- 230000003281 allosteric effect Effects 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical compound NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 description 12
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 11
- 229910052794 bromium Inorganic materials 0.000 description 11
- 230000008878 coupling Effects 0.000 description 11
- 238000010168 coupling process Methods 0.000 description 11
- 238000005859 coupling reaction Methods 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 235000019441 ethanol Nutrition 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 229910000027 potassium carbonate Inorganic materials 0.000 description 11
- 229910000077 silane Inorganic materials 0.000 description 11
- 239000012279 sodium borohydride Substances 0.000 description 11
- 229910000033 sodium borohydride Inorganic materials 0.000 description 11
- WBQTXTBONIWRGK-UHFFFAOYSA-N sodium;propan-2-olate Chemical compound [Na+].CC(C)[O-] WBQTXTBONIWRGK-UHFFFAOYSA-N 0.000 description 11
- 201000004624 Dermatitis Diseases 0.000 description 10
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 10
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 10
- 150000001408 amides Chemical class 0.000 description 10
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 10
- 230000001684 chronic effect Effects 0.000 description 10
- 150000002012 dioxanes Chemical class 0.000 description 10
- 239000001257 hydrogen Substances 0.000 description 10
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 10
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 9
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 9
- 125000004429 atom Chemical group 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 239000003638 chemical reducing agent Substances 0.000 description 9
- 239000013058 crude material Substances 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 238000006467 substitution reaction Methods 0.000 description 9
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 8
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 8
- 229910019142 PO4 Inorganic materials 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 230000005587 bubbling Effects 0.000 description 8
- XTEOJPUYZWEXFI-UHFFFAOYSA-N butyl n-[3-[4-(imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamate Chemical compound S1C(CC(C)C)=CC(C=2C=CC(CN3C=NC=C3)=CC=2)=C1S(=O)(=O)NC(=O)OCCCC XTEOJPUYZWEXFI-UHFFFAOYSA-N 0.000 description 8
- 125000004122 cyclic group Chemical group 0.000 description 8
- 239000003085 diluting agent Substances 0.000 description 8
- 229940113088 dimethylacetamide Drugs 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 230000002757 inflammatory effect Effects 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 239000000543 intermediate Substances 0.000 description 8
- 239000010452 phosphate Substances 0.000 description 8
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 8
- 238000010898 silica gel chromatography Methods 0.000 description 8
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 8
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 8
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 7
- 125000002252 acyl group Chemical group 0.000 description 7
- 125000003342 alkenyl group Chemical group 0.000 description 7
- 239000005557 antagonist Substances 0.000 description 7
- 230000001363 autoimmune Effects 0.000 description 7
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 7
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 7
- 239000007789 gas Substances 0.000 description 7
- 125000002883 imidazolyl group Chemical group 0.000 description 7
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 7
- 125000003226 pyrazolyl group Chemical group 0.000 description 7
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 7
- 238000001953 recrystallisation Methods 0.000 description 7
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 description 7
- 125000000335 thiazolyl group Chemical group 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- QUPBUWPFQNEAJR-UHFFFAOYSA-N 5-(5-bromo-1,3,4-thiadiazol-2-yl)-2-fluorobenzonitrile Chemical compound C1=C(C#N)C(F)=CC=C1C1=NN=C(Br)S1 QUPBUWPFQNEAJR-UHFFFAOYSA-N 0.000 description 6
- MDGUJEYGTKRXBV-UHFFFAOYSA-N 5-(5-bromo-1,3-thiazol-2-yl)-2-fluorobenzonitrile Chemical compound C1=C(C#N)C(F)=CC=C1C1=NC=C(Br)S1 MDGUJEYGTKRXBV-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 206010018364 Glomerulonephritis Diseases 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 206010019663 Hepatic failure Diseases 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 201000004681 Psoriasis Diseases 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- 230000003213 activating effect Effects 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 6
- 150000001721 carbon Chemical group 0.000 description 6
- 125000000392 cycloalkenyl group Chemical group 0.000 description 6
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 6
- ZCRZCMUDOWDGOB-UHFFFAOYSA-N ethanesulfonimidic acid Chemical compound CCS(N)(=O)=O ZCRZCMUDOWDGOB-UHFFFAOYSA-N 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 208000007903 liver failure Diseases 0.000 description 6
- 231100000835 liver failure Toxicity 0.000 description 6
- PYFSLJVSCGXYAJ-UHFFFAOYSA-N methyl 2-hydroxy-4-[[3-(2-hydroxyphenyl)phenyl]sulfonylamino]benzoate Chemical compound C1=C(O)C(C(=O)OC)=CC=C1NS(=O)(=O)C1=CC=CC(C=2C(=CC=CC=2)O)=C1 PYFSLJVSCGXYAJ-UHFFFAOYSA-N 0.000 description 6
- 125000002757 morpholinyl group Chemical group 0.000 description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 125000003386 piperidinyl group Chemical group 0.000 description 6
- 239000000018 receptor agonist Substances 0.000 description 6
- 229940044601 receptor agonist Drugs 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 238000006722 reduction reaction Methods 0.000 description 6
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 5
- WUIJTQZXUURFQU-UHFFFAOYSA-N 1-methylsulfonylethene Chemical compound CS(=O)(=O)C=C WUIJTQZXUURFQU-UHFFFAOYSA-N 0.000 description 5
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 5
- PVUYNFQZHNNZLT-UHFFFAOYSA-N 2-propan-2-yloxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1B1OC(C)(C)C(C)(C)O1 PVUYNFQZHNNZLT-UHFFFAOYSA-N 0.000 description 5
- NGMDRYNYDHYKMG-UHFFFAOYSA-N 5-[4-[1-[tert-butyl(dimethyl)silyl]oxy-2,3-dihydro-1h-inden-4-yl]thiophen-2-yl]-2-propan-2-yloxybenzonitrile Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=CC(C=2C=3CCC(C=3C=CC=2)O[Si](C)(C)C(C)(C)C)=CS1 NGMDRYNYDHYKMG-UHFFFAOYSA-N 0.000 description 5
- ZUGKGRKDVSIGFR-FYZYNONXSA-N 5-[5-[(5s)-5-amino-5,6,7,8-tetrahydronaphthalen-1-yl]-1,3,4-thiadiazol-2-yl]-2-propan-2-yloxybenzonitrile;hydrochloride Chemical compound Cl.C1=C(C#N)C(OC(C)C)=CC=C1C1=NN=C(C=2C=3CCC[C@H](N)C=3C=CC=2)S1 ZUGKGRKDVSIGFR-FYZYNONXSA-N 0.000 description 5
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 5
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 5
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 5
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 5
- 239000007821 HATU Substances 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 150000001298 alcohols Chemical class 0.000 description 5
- 125000000304 alkynyl group Chemical group 0.000 description 5
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 5
- 150000001768 cations Chemical class 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 229910052731 fluorine Inorganic materials 0.000 description 5
- 238000007429 general method Methods 0.000 description 5
- YIAPLDFPUUJILH-UHFFFAOYSA-N indan-1-ol Chemical compound C1=CC=C2C(O)CCC2=C1 YIAPLDFPUUJILH-UHFFFAOYSA-N 0.000 description 5
- 125000001041 indolyl group Chemical group 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 229910052740 iodine Inorganic materials 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 125000003367 polycyclic group Chemical group 0.000 description 5
- 235000011056 potassium acetate Nutrition 0.000 description 5
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 5
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 5
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 description 5
- 229940124530 sulfonamide Drugs 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- RNXQQZNOSYBFTN-VIFPVBQESA-N (1s)-4-bromo-2,3-dihydro-1h-inden-1-ol Chemical compound C1=CC=C(Br)C2=C1[C@@H](O)CC2 RNXQQZNOSYBFTN-VIFPVBQESA-N 0.000 description 4
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 4
- JTAROQGOUCFPBV-UHFFFAOYSA-N 2,3-dihydro-1h-indene-1-sulfonamide Chemical class C1=CC=C2C(S(=O)(=O)N)CCC2=C1 JTAROQGOUCFPBV-UHFFFAOYSA-N 0.000 description 4
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- JBKINHFZTVLNEM-UHFFFAOYSA-N 2-bromoethoxy-tert-butyl-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCCBr JBKINHFZTVLNEM-UHFFFAOYSA-N 0.000 description 4
- DQSRVWNGCNSDNE-UHFFFAOYSA-N 3-(pyridin-3-ylamino)propyl 4-[[3-(5-fluoro-2-hydroxyphenyl)phenyl]sulfonylamino]-2-hydroxybenzoate Chemical compound OC1=CC=C(F)C=C1C1=CC=CC(S(=O)(=O)NC=2C=C(O)C(C(=O)OCCCNC=3C=NC=CC=3)=CC=2)=C1 DQSRVWNGCNSDNE-UHFFFAOYSA-N 0.000 description 4
- HEGSTOGQZIPFFV-UHFFFAOYSA-N 5-(5-amino-1,3,4-thiadiazol-2-yl)-2-fluorobenzonitrile Chemical compound S1C(N)=NN=C1C1=CC=C(F)C(C#N)=C1 HEGSTOGQZIPFFV-UHFFFAOYSA-N 0.000 description 4
- MFARJOUZIHWIBP-UHFFFAOYSA-N 5-(5-bromothiophen-2-yl)-2-propan-2-yloxybenzonitrile Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=CC=C(Br)S1 MFARJOUZIHWIBP-UHFFFAOYSA-N 0.000 description 4
- HAADVQLQVHKMRH-UHFFFAOYSA-N 5-[5-(1-hydroxy-2,3-dihydro-1h-inden-4-yl)thiophen-2-yl]-2-propan-2-yloxybenzonitrile Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=CC=C(C=2C=3CCC(O)C=3C=CC=2)S1 HAADVQLQVHKMRH-UHFFFAOYSA-N 0.000 description 4
- YGGIHRUSSWAGBG-SANMLTNESA-N 5-[5-[(1s)-1-[2-[tert-butyl(dimethyl)silyl]oxyethylamino]-2,3-dihydro-1h-inden-4-yl]-1,3-thiazol-2-yl]-2-propan-2-yloxybenzonitrile Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NC=C(C=2C=3CC[C@@H](C=3C=CC=2)NCCO[Si](C)(C)C(C)(C)C)S1 YGGIHRUSSWAGBG-SANMLTNESA-N 0.000 description 4
- YIDAVWGHLSRPLC-DEOSSOPVSA-N 5-[5-[(1s)-1-[tert-butyl(dimethyl)silyl]oxy-2,3-dihydro-1h-inden-4-yl]-1,3,4-thiadiazol-2-yl]-2-propan-2-yloxybenzonitrile Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NN=C(C=2C=3CC[C@@H](C=3C=CC=2)O[Si](C)(C)C(C)(C)C)S1 YIDAVWGHLSRPLC-DEOSSOPVSA-N 0.000 description 4
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 4
- 201000004384 Alopecia Diseases 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- 208000032467 Aplastic anaemia Diseases 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- 206010015150 Erythema Diseases 0.000 description 4
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 4
- 208000009329 Graft vs Host Disease Diseases 0.000 description 4
- 229910004373 HOAc Inorganic materials 0.000 description 4
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 4
- 206010020850 Hyperthyroidism Diseases 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 206010029240 Neuritis Diseases 0.000 description 4
- 241000721454 Pemphigus Species 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- 206010064996 Ulcerative keratitis Diseases 0.000 description 4
- 206010046851 Uveitis Diseases 0.000 description 4
- UCQYOHXQSIUXBL-UHFFFAOYSA-N [4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-1H-inden-1-yl]carbamic acid Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=CC2=C1CCC2NC(O)=O UCQYOHXQSIUXBL-UHFFFAOYSA-N 0.000 description 4
- 125000003710 aryl alkyl group Chemical group 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 125000002837 carbocyclic group Chemical group 0.000 description 4
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 4
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical group [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 4
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 231100000321 erythema Toxicity 0.000 description 4
- PTCGDEVVHUXTMP-UHFFFAOYSA-N flutolanil Chemical compound CC(C)OC1=CC=CC(NC(=O)C=2C(=CC=CC=2)C(F)(F)F)=C1 PTCGDEVVHUXTMP-UHFFFAOYSA-N 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 208000023589 ischemic disease Diseases 0.000 description 4
- 206010023332 keratitis Diseases 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- QSRRZKPKHJHIRB-UHFFFAOYSA-N methyl 4-[(2,5-dichloro-4-methylthiophen-3-yl)sulfonylamino]-2-hydroxybenzoate Chemical compound C1=C(O)C(C(=O)OC)=CC=C1NS(=O)(=O)C1=C(Cl)SC(Cl)=C1C QSRRZKPKHJHIRB-UHFFFAOYSA-N 0.000 description 4
- YGDGZDGRCWHDOU-UHFFFAOYSA-N methyl 4-[[5-chloro-4-(2-hydroxyphenyl)thiophen-2-yl]sulfonylamino]-2-hydroxybenzoate Chemical compound C1=C(O)C(C(=O)OC)=CC=C1NS(=O)(=O)C1=CC(C=2C(=CC=CC=2)O)=C(Cl)S1 YGDGZDGRCWHDOU-UHFFFAOYSA-N 0.000 description 4
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 4
- 206010028417 myasthenia gravis Diseases 0.000 description 4
- 201000005962 mycosis fungoides Diseases 0.000 description 4
- PHYXLVBKNLQJFR-FQEVSTJZSA-N n-[(1s)-4-[5-(3-cyano-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-2,3-dihydro-1h-inden-1-yl]ethenesulfonamide Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NN=C(C=2C=3CC[C@@H](C=3C=CC=2)NS(=O)(=O)C=C)S1 PHYXLVBKNLQJFR-FQEVSTJZSA-N 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 125000004430 oxygen atom Chemical group O* 0.000 description 4
- HFPZCAJZSCWRBC-UHFFFAOYSA-N p-cymene Chemical compound CC(C)C1=CC=C(C)C=C1 HFPZCAJZSCWRBC-UHFFFAOYSA-N 0.000 description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 239000003223 protective agent Substances 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 201000003068 rheumatic fever Diseases 0.000 description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 125000003107 substituted aryl group Chemical group 0.000 description 4
- 125000001010 sulfinic acid amide group Chemical group 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- JEDJGVSGTZKGFJ-JTQLQIEISA-N (1s)-5-bromo-1,2,3,4-tetrahydronaphthalen-1-ol Chemical compound C1=CC=C2[C@@H](O)CCCC2=C1Br JEDJGVSGTZKGFJ-JTQLQIEISA-N 0.000 description 3
- ZMFIWVJZUSQMBE-UHFFFAOYSA-N (3-cyano-4-propan-2-yloxyphenyl)boronic acid Chemical compound CC(C)OC1=CC=C(B(O)O)C=C1C#N ZMFIWVJZUSQMBE-UHFFFAOYSA-N 0.000 description 3
- VMKAFJQFKBASMU-QGZVFWFLSA-N (r)-2-methyl-cbs-oxazaborolidine Chemical compound C([C@@H]12)CCN1B(C)OC2(C=1C=CC=CC=1)C1=CC=CC=C1 VMKAFJQFKBASMU-QGZVFWFLSA-N 0.000 description 3
- OFZMOQOOTWYMOU-SFHVURJKSA-N 2-(3-cyano-4-propan-2-yloxyphenyl)-5-[(1s)-1-(sulfamoylamino)-2,3-dihydro-1h-inden-4-yl]-1,3,4-thiadiazole Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NN=C(C=2C=3CC[C@@H](C=3C=CC=2)NS(N)(=O)=O)S1 OFZMOQOOTWYMOU-SFHVURJKSA-N 0.000 description 3
- MZOUSYJVPWNFPQ-QHCPKHFHSA-N 2-[[(1s)-4-[2-(3-cyano-4-propan-2-yloxyphenyl)-1,3-thiazol-5-yl]-2,3-dihydro-1h-inden-1-yl]-[(2-methylpropan-2-yl)oxycarbonyl]amino]acetic acid Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NC=C(C=2C=3CC[C@@H](C=3C=CC=2)N(CC(O)=O)C(=O)OC(C)(C)C)S1 MZOUSYJVPWNFPQ-QHCPKHFHSA-N 0.000 description 3
- OKYCCHHLENDCLM-QFIPXVFZSA-N 2-[[(1s)-4-[5-(3-cyano-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-2,3-dihydro-1h-inden-1-yl]-[(2-methylpropan-2-yl)oxycarbonyl]amino]acetic acid Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NN=C(C=2C=3CC[C@@H](C=3C=CC=2)N(CC(O)=O)C(=O)OC(C)(C)C)S1 OKYCCHHLENDCLM-QFIPXVFZSA-N 0.000 description 3
- ZPTGJSQGEUJZJP-UHFFFAOYSA-N 2-fluoro-5-(1,3-thiazol-2-yl)benzonitrile Chemical compound C1=C(C#N)C(F)=CC=C1C1=NC=CS1 ZPTGJSQGEUJZJP-UHFFFAOYSA-N 0.000 description 3
- GKIAYVIMOAIQRN-UHFFFAOYSA-N 2-fluoro-5-(1,3-thiazol-5-yl)benzonitrile Chemical compound C1=C(C#N)C(F)=CC=C1C1=CN=CS1 GKIAYVIMOAIQRN-UHFFFAOYSA-N 0.000 description 3
- LUWQEXMGFHUNIM-UHFFFAOYSA-N 2-propan-2-yloxy-5-thiophen-2-ylbenzonitrile Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=CC=CS1 LUWQEXMGFHUNIM-UHFFFAOYSA-N 0.000 description 3
- JMHGATOBRPWPBZ-UHFFFAOYSA-N 3-cyano-4-fluorobenzoic acid Chemical compound OC(=O)C1=CC=C(F)C(C#N)=C1 JMHGATOBRPWPBZ-UHFFFAOYSA-N 0.000 description 3
- 125000001963 4 membered heterocyclic group Chemical group 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- UVVYFYLSZIMKMC-UHFFFAOYSA-N 4-bromo-2,3-dihydroinden-1-one Chemical compound BrC1=CC=CC2=C1CCC2=O UVVYFYLSZIMKMC-UHFFFAOYSA-N 0.000 description 3
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 3
- FKQPHPUDNZXCBL-UHFFFAOYSA-N 5-(2-bromo-1,3-thiazol-5-yl)-2-fluorobenzonitrile Chemical compound C1=C(C#N)C(F)=CC=C1C1=CN=C(Br)S1 FKQPHPUDNZXCBL-UHFFFAOYSA-N 0.000 description 3
- SMRWEEKBBPOQBZ-UHFFFAOYSA-N 5-(3-bromo-1,2,4-thiadiazol-5-yl)-2-propan-2-yloxybenzonitrile Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NC(Br)=NS1 SMRWEEKBBPOQBZ-UHFFFAOYSA-N 0.000 description 3
- IKWYQCJGMWRWOZ-SFHVURJKSA-N 5-(3-cyano-4-propan-2-yloxyphenyl)-3-[(1s)-1-(sulfamoylamino)-2,3-dihydro-1h-inden-4-yl]-1,2,4-thiadiazole Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NC(C=2C=3CC[C@@H](C=3C=CC=2)NS(N)(=O)=O)=NS1 IKWYQCJGMWRWOZ-SFHVURJKSA-N 0.000 description 3
- PJSDOBZBIRGQAY-UHFFFAOYSA-N 5-(4-bromothiophen-2-yl)-2-propan-2-yloxybenzonitrile Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=CC(Br)=CS1 PJSDOBZBIRGQAY-UHFFFAOYSA-N 0.000 description 3
- OBCPVVFGNKMVNN-UHFFFAOYSA-N 5-[2-(1-hydroxy-2,3-dihydro-1h-inden-4-yl)-1,3-thiazol-5-yl]-2-propan-2-yloxybenzonitrile Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=CN=C(C=2C=3CCC(O)C=3C=CC=2)S1 OBCPVVFGNKMVNN-UHFFFAOYSA-N 0.000 description 3
- ODNZSRIOLUDAAG-UHFFFAOYSA-N 5-[5-(1-hydroxy-2,3-dihydro-1h-inden-4-yl)thiophen-3-yl]-2-propan-2-yloxybenzonitrile Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=CSC(C=2C=3CCC(O)C=3C=CC=2)=C1 ODNZSRIOLUDAAG-UHFFFAOYSA-N 0.000 description 3
- NHFKYRYFDXPBDR-GMUIIQOCSA-N 5-[5-[(1r)-1-amino-2,3-dihydro-1h-inden-4-yl]-1,3,4-thiadiazol-2-yl]-2-propan-2-yloxybenzonitrile;hydrochloride Chemical compound Cl.C1=C(C#N)C(OC(C)C)=CC=C1C1=NN=C(C=2C=3CC[C@@H](N)C=3C=CC=2)S1 NHFKYRYFDXPBDR-GMUIIQOCSA-N 0.000 description 3
- VTRPTBUUJXGTBC-RDPSFJRHSA-N 5-[5-[(1s)-1-[[2-[(3s)-3-hydroxypyrrolidin-1-yl]-2-oxoethyl]amino]-2,3-dihydro-1h-inden-4-yl]-1,3-thiazol-2-yl]-2-propan-2-yloxybenzonitrile Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NC=C(C=2C=3CC[C@@H](C=3C=CC=2)NCC(=O)N2C[C@@H](O)CC2)S1 VTRPTBUUJXGTBC-RDPSFJRHSA-N 0.000 description 3
- YRPPYKWHWKFYGJ-UHFFFAOYSA-N 5-bromo-2-propan-2-yloxybenzonitrile Chemical compound CC(C)OC1=CC=C(Br)C=C1C#N YRPPYKWHWKFYGJ-UHFFFAOYSA-N 0.000 description 3
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- UQAHKQHYSNHGKN-QHCPKHFHSA-N C(C)(C)(C)OC(=O)N(CC(=O)O)[C@H]1CCCC2=C(C=CC=C12)C=1SC(=NN1)C1=CC(=C(C=C1)OC(C)C)C#N Chemical compound C(C)(C)(C)OC(=O)N(CC(=O)O)[C@H]1CCCC2=C(C=CC=C12)C=1SC(=NN1)C1=CC(=C(C=C1)OC(C)C)C#N UQAHKQHYSNHGKN-QHCPKHFHSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 206010025327 Lymphopenia Diseases 0.000 description 3
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 150000001336 alkenes Chemical class 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000002860 competitive effect Effects 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 150000003840 hydrochlorides Chemical class 0.000 description 3
- 239000003018 immunosuppressive agent Substances 0.000 description 3
- 125000000842 isoxazolyl group Chemical group 0.000 description 3
- 231100001023 lymphopenia Toxicity 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 3
- YBIPZPBGAGTBGK-UHFFFAOYSA-N methyl 2-chlorosulfonylacetate Chemical compound COC(=O)CS(Cl)(=O)=O YBIPZPBGAGTBGK-UHFFFAOYSA-N 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- OOGFKXCTRSASQJ-HXUWFJFHSA-N n-[(1r)-4-[5-(3-cyano-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-2,3-dihydro-1h-inden-1-yl]-2-hydroxyethanesulfonamide Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NN=C(C=2C=3CC[C@H](C=3C=CC=2)NS(=O)(=O)CCO)S1 OOGFKXCTRSASQJ-HXUWFJFHSA-N 0.000 description 3
- IUFJURNENMPFKE-FQEVSTJZSA-N n-[(1s)-4-[5-(3-cyano-4-propan-2-yloxyphenyl)-1,2,4-thiadiazol-3-yl]-2,3-dihydro-1h-inden-1-yl]-2-hydroxyethanesulfonamide Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NC(C=2C=3CC[C@@H](C=3C=CC=2)NS(=O)(=O)CCO)=NS1 IUFJURNENMPFKE-FQEVSTJZSA-N 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- 125000004193 piperazinyl group Chemical group 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 238000004237 preparative chromatography Methods 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 150000003456 sulfonamides Chemical class 0.000 description 3
- 150000003457 sulfones Chemical class 0.000 description 3
- 125000004496 thiazol-5-yl group Chemical group S1C=NC=C1* 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- 125000001425 triazolyl group Chemical group 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- OGDOHVPGFOSYEH-SNVBAGLBSA-N (1r)-1-azido-5-bromo-1,2,3,4-tetrahydronaphthalene Chemical compound [N-]=[N+]=N[C@@H]1CCCC2=C1C=CC=C2Br OGDOHVPGFOSYEH-SNVBAGLBSA-N 0.000 description 2
- RNXQQZNOSYBFTN-SECBINFHSA-N (1r)-4-bromo-2,3-dihydro-1h-inden-1-ol Chemical compound C1=CC=C(Br)C2=C1[C@H](O)CC2 RNXQQZNOSYBFTN-SECBINFHSA-N 0.000 description 2
- JEDJGVSGTZKGFJ-SNVBAGLBSA-N (1r)-5-bromo-1,2,3,4-tetrahydronaphthalen-1-ol Chemical compound C1=CC=C2[C@H](O)CCCC2=C1Br JEDJGVSGTZKGFJ-SNVBAGLBSA-N 0.000 description 2
- OGDOHVPGFOSYEH-JTQLQIEISA-N (1s)-1-azido-5-bromo-1,2,3,4-tetrahydronaphthalene Chemical compound [N-]=[N+]=N[C@H]1CCCC2=C1C=CC=C2Br OGDOHVPGFOSYEH-JTQLQIEISA-N 0.000 description 2
- RTHLDTMQQDLJCE-UHFFFAOYSA-N (2-oxo-2-pyrrolidin-1-ylethyl) carbamate Chemical compound C(N)(OCC(=O)N1CCCC1)=O RTHLDTMQQDLJCE-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 description 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 2
- GHHOTNZAUWEDEV-VMEIHUARSA-N (ne)-n-(4-bromo-2,3-dihydroinden-1-ylidene)-2-methylpropane-2-sulfinamide Chemical compound C1=CC=C(Br)C2=C1C(=N/[S@@](=O)C(C)(C)C)/CC2 GHHOTNZAUWEDEV-VMEIHUARSA-N 0.000 description 2
- SRYALXBZLHTHHG-UHFFFAOYSA-N 1,2,3,4-tetrahydronaphthalene-1-sulfonamide Chemical class C1=CC=C2C(S(=O)(=O)N)CCCC2=C1 SRYALXBZLHTHHG-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 description 2
- XJEVHMGJSYVQBQ-UHFFFAOYSA-N 2,3-dihydro-1h-inden-1-amine Chemical compound C1=CC=C2C(N)CCC2=C1 XJEVHMGJSYVQBQ-UHFFFAOYSA-N 0.000 description 2
- WAQFYSJKIRRXLP-UHFFFAOYSA-N 2,4-dibromothiophene Chemical compound BrC1=CSC(Br)=C1 WAQFYSJKIRRXLP-UHFFFAOYSA-N 0.000 description 2
- FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 2
- QGPSKHKXNLIWNQ-LJQANCHMSA-N 2-(3-cyano-4-propan-2-yloxyphenyl)-5-[(1r)-1-(sulfamoylamino)-2,3-dihydro-1h-inden-4-yl]-1,3-thiazole Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NC=C(C=2C=3CC[C@H](C=3C=CC=2)NS(N)(=O)=O)S1 QGPSKHKXNLIWNQ-LJQANCHMSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- OKYCCHHLENDCLM-JOCHJYFZSA-N 2-[[(1r)-4-[5-(3-cyano-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-2,3-dihydro-1h-inden-1-yl]-[(2-methylpropan-2-yl)oxycarbonyl]amino]acetic acid Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NN=C(C=2C=3CC[C@H](C=3C=CC=2)N(CC(O)=O)C(=O)OC(C)(C)C)S1 OKYCCHHLENDCLM-JOCHJYFZSA-N 0.000 description 2
- LBVMDDWIJRAABB-OAQYLSRUSA-N 2-[[(1r)-4-[5-(3-cyano-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-2,3-dihydro-1h-inden-1-yl]sulfamoyl]-n,n-dimethylacetamide Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NN=C(C=2C=3CC[C@H](C=3C=CC=2)NS(=O)(=O)CC(=O)N(C)C)S1 LBVMDDWIJRAABB-OAQYLSRUSA-N 0.000 description 2
- WAEPJWRDRZCEQD-LJQANCHMSA-N 2-[[(1r)-4-[5-(3-cyano-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-2,3-dihydro-1h-inden-1-yl]sulfamoyl]acetic acid Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NN=C(C=2C=3CC[C@H](C=3C=CC=2)NS(=O)(=O)CC(O)=O)S1 WAEPJWRDRZCEQD-LJQANCHMSA-N 0.000 description 2
- UQAHKQHYSNHGKN-HSZRJFAPSA-N 2-[[(1r)-5-[5-(3-cyano-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-1,2,3,4-tetrahydronaphthalen-1-yl]-[(2-methylpropan-2-yl)oxycarbonyl]amino]acetic acid Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NN=C(C=2C=3CCC[C@H](C=3C=CC=2)N(CC(O)=O)C(=O)OC(C)(C)C)S1 UQAHKQHYSNHGKN-HSZRJFAPSA-N 0.000 description 2
- UDKDVOVOZAFTMN-HXUWFJFHSA-N 2-[[(1r)-5-[5-(3-cyano-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-1,2,3,4-tetrahydronaphthalen-1-yl]sulfamoyl]acetic acid Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NN=C(C=2C=3CCC[C@H](C=3C=CC=2)NS(=O)(=O)CC(O)=O)S1 UDKDVOVOZAFTMN-HXUWFJFHSA-N 0.000 description 2
- WAEPJWRDRZCEQD-IBGZPJMESA-N 2-[[(1s)-4-[5-(3-cyano-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-2,3-dihydro-1h-inden-1-yl]sulfamoyl]acetic acid Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NN=C(C=2C=3CC[C@@H](C=3C=CC=2)NS(=O)(=O)CC(O)=O)S1 WAEPJWRDRZCEQD-IBGZPJMESA-N 0.000 description 2
- RXNZFHIEDZEUQM-UHFFFAOYSA-N 2-bromo-1,3-thiazole Chemical compound BrC1=NC=CS1 RXNZFHIEDZEUQM-UHFFFAOYSA-N 0.000 description 2
- AYNCWMIFKFADCZ-UHFFFAOYSA-N 2-bromo-3,4-dihydro-2h-naphthalen-1-one Chemical compound C1=CC=C2C(=O)C(Br)CCC2=C1 AYNCWMIFKFADCZ-UHFFFAOYSA-N 0.000 description 2
- KQHVGSGBOURORB-UHFFFAOYSA-N 2-bromo-5-(3,4-diethoxyphenyl)-1,3,4-thiadiazole Chemical compound C1=C(OCC)C(OCC)=CC=C1C1=NN=C(Br)S1 KQHVGSGBOURORB-UHFFFAOYSA-N 0.000 description 2
- VHCSBTPOPKFYIU-UHFFFAOYSA-N 2-chloroethanesulfonyl chloride Chemical compound ClCCS(Cl)(=O)=O VHCSBTPOPKFYIU-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- CESUXLKAADQNTB-SSDOTTSWSA-N 2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@](N)=O CESUXLKAADQNTB-SSDOTTSWSA-N 0.000 description 2
- CESUXLKAADQNTB-ZETCQYMHSA-N 2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](N)=O CESUXLKAADQNTB-ZETCQYMHSA-N 0.000 description 2
- VVKCVAPLTRZJHH-UHFFFAOYSA-N 3,4-diethoxybenzoic acid Chemical compound CCOC1=CC=C(C(O)=O)C=C1OCC VVKCVAPLTRZJHH-UHFFFAOYSA-N 0.000 description 2
- LZPWAYBEOJRFAX-UHFFFAOYSA-N 4,4,5,5-tetramethyl-1,3,2$l^{2}-dioxaborolane Chemical compound CC1(C)O[B]OC1(C)C LZPWAYBEOJRFAX-UHFFFAOYSA-N 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- ZHPUDNZICKPJAE-UHFFFAOYSA-N 5-(3,4-diethoxyphenyl)-1,3,4-thiadiazol-2-amine Chemical compound C1=C(OCC)C(OCC)=CC=C1C1=NN=C(N)S1 ZHPUDNZICKPJAE-UHFFFAOYSA-N 0.000 description 2
- RRKUMMKYULFGPN-FSRHSHDFSA-N 5-[2-[(1r)-1-amino-2,3-dihydro-1h-inden-4-yl]-1,3-thiazol-5-yl]-2-propan-2-yloxybenzonitrile;hydrochloride Chemical compound Cl.C1=C(C#N)C(OC(C)C)=CC=C1C1=CN=C(C=2C=3CC[C@@H](N)C=3C=CC=2)S1 RRKUMMKYULFGPN-FSRHSHDFSA-N 0.000 description 2
- RRKUMMKYULFGPN-FYZYNONXSA-N 5-[2-[(1s)-1-amino-2,3-dihydro-1h-inden-4-yl]-1,3-thiazol-5-yl]-2-propan-2-yloxybenzonitrile;hydrochloride Chemical compound Cl.C1=C(C#N)C(OC(C)C)=CC=C1C1=CN=C(C=2C=3CC[C@H](N)C=3C=CC=2)S1 RRKUMMKYULFGPN-FYZYNONXSA-N 0.000 description 2
- NRCHRMRBBBRNJG-UHFFFAOYSA-N 5-[2-[1-[tert-butyl(dimethyl)silyl]oxy-2,3-dihydro-1h-inden-4-yl]-1,3-thiazol-5-yl]-2-fluorobenzonitrile Chemical compound CC(C)(C)[Si](C)(C)OC1CCC2=C1C=CC=C2C(S1)=NC=C1C1=CC=C(F)C(C#N)=C1 NRCHRMRBBBRNJG-UHFFFAOYSA-N 0.000 description 2
- DBESPDHARCIHKV-UHFFFAOYSA-N 5-[2-[1-[tert-butyl(dimethyl)silyl]oxy-2,3-dihydro-1h-inden-4-yl]-1,3-thiazol-5-yl]-2-propan-2-yloxybenzonitrile Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=CN=C(C=2C=3CCC(C=3C=CC=2)O[Si](C)(C)C(C)(C)C)S1 DBESPDHARCIHKV-UHFFFAOYSA-N 0.000 description 2
- DBIYMESCOFLEBW-JGCGQSQUSA-N 5-[3-[(1R)-1-[bis[2-[tert-butyl(dimethyl)silyl]oxyethyl]amino]-2,3-dihydro-1H-inden-4-yl]-1,2,4-thiadiazol-5-yl]-2-propan-2-yloxybenzonitrile Chemical compound C(C)(C)(C)[Si](OCCN([C@@H]1CCC2=C(C=CC=C12)C1=NSC(=N1)C=1C=CC(=C(C#N)C1)OC(C)C)CCO[Si](C(C)(C)C)(C)C)(C)C DBIYMESCOFLEBW-JGCGQSQUSA-N 0.000 description 2
- DBIYMESCOFLEBW-YTTGMZPUSA-N 5-[3-[(1s)-1-[bis[2-[tert-butyl(dimethyl)silyl]oxyethyl]amino]-2,3-dihydro-1h-inden-4-yl]-1,2,4-thiadiazol-5-yl]-2-propan-2-yloxybenzonitrile Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NC(C=2C=3CC[C@@H](C=3C=CC=2)N(CCO[Si](C)(C)C(C)(C)C)CCO[Si](C)(C)C(C)(C)C)=NS1 DBIYMESCOFLEBW-YTTGMZPUSA-N 0.000 description 2
- HYPXRWFJBBEIPV-UHFFFAOYSA-N 5-[4-(1-hydroxy-2,3-dihydro-1h-inden-4-yl)thiophen-2-yl]-2-propan-2-yloxybenzonitrile Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=CC(C=2C=3CCC(O)C=3C=CC=2)=CS1 HYPXRWFJBBEIPV-UHFFFAOYSA-N 0.000 description 2
- YGGIHRUSSWAGBG-AREMUKBSSA-N 5-[5-[(1r)-1-[2-[tert-butyl(dimethyl)silyl]oxyethylamino]-2,3-dihydro-1h-inden-4-yl]-1,3-thiazol-2-yl]-2-propan-2-yloxybenzonitrile Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NC=C(C=2C=3CC[C@H](C=3C=CC=2)NCCO[Si](C)(C)C(C)(C)C)S1 YGGIHRUSSWAGBG-AREMUKBSSA-N 0.000 description 2
- ZCLZVXFAXGCCLI-FSRHSHDFSA-N 5-[5-[(1r)-1-amino-2,3-dihydro-1h-inden-4-yl]-1,3-thiazol-2-yl]-2-propan-2-yloxybenzonitrile;hydrochloride Chemical compound Cl.C1=C(C#N)C(OC(C)C)=CC=C1C1=NC=C(C=2C=3CC[C@@H](N)C=3C=CC=2)S1 ZCLZVXFAXGCCLI-FSRHSHDFSA-N 0.000 description 2
- QMTJBVPEPUIHRS-NRFANRHFSA-N 5-[5-[(1s)-1-(1h-imidazol-2-ylmethylamino)-2,3-dihydro-1h-inden-4-yl]-1,3,4-thiadiazol-2-yl]-2-propan-2-yloxybenzonitrile Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NN=C(C=2C=3CC[C@@H](C=3C=CC=2)NCC=2NC=CN=2)S1 QMTJBVPEPUIHRS-NRFANRHFSA-N 0.000 description 2
- HZDWXOVDJKIEMR-FERBBOLQSA-N 5-[5-[(1s)-1-amino-2,3-dihydro-1h-inden-4-yl]-1,2,4-thiadiazol-3-yl]-2-propan-2-yloxybenzonitrile;hydrochloride Chemical compound Cl.C1=C(C#N)C(OC(C)C)=CC=C1C1=NSC(C=2C=3CC[C@H](N)C=3C=CC=2)=N1 HZDWXOVDJKIEMR-FERBBOLQSA-N 0.000 description 2
- FPJWIJWMNQLJQF-IBGZPJMESA-N 5-[5-[(1s)-1-amino-2,3-dihydro-1h-inden-4-yl]-1,3-thiazol-2-yl]-2-propan-2-yloxybenzonitrile Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NC=C(C=2C=3CC[C@H](N)C=3C=CC=2)S1 FPJWIJWMNQLJQF-IBGZPJMESA-N 0.000 description 2
- ZCLZVXFAXGCCLI-FYZYNONXSA-N 5-[5-[(1s)-1-amino-2,3-dihydro-1h-inden-4-yl]-1,3-thiazol-2-yl]-2-propan-2-yloxybenzonitrile;hydrochloride Chemical compound Cl.C1=C(C#N)C(OC(C)C)=CC=C1C1=NC=C(C=2C=3CC[C@H](N)C=3C=CC=2)S1 ZCLZVXFAXGCCLI-FYZYNONXSA-N 0.000 description 2
- AWOMQWTXBCOFDO-IBGZPJMESA-N 5-[5-[(1s)-1-hydroxy-2,3-dihydro-1h-inden-4-yl]-1,3-thiazol-2-yl]-2-propan-2-yloxybenzonitrile Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NC=C(C=2C=3CC[C@H](O)C=3C=CC=2)S1 AWOMQWTXBCOFDO-IBGZPJMESA-N 0.000 description 2
- ADCDSKJZIYYBKO-LJQANCHMSA-N 5-[5-[(5r)-5-amino-5,6,7,8-tetrahydronaphthalen-1-yl]-1,3,4-thiadiazol-2-yl]-2-propan-2-yloxybenzonitrile Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NN=C(C=2C=3CCC[C@@H](N)C=3C=CC=2)S1 ADCDSKJZIYYBKO-LJQANCHMSA-N 0.000 description 2
- ADCDSKJZIYYBKO-IBGZPJMESA-N 5-[5-[(5s)-5-amino-5,6,7,8-tetrahydronaphthalen-1-yl]-1,3,4-thiadiazol-2-yl]-2-propan-2-yloxybenzonitrile Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NN=C(C=2C=3CCC[C@H](N)C=3C=CC=2)S1 ADCDSKJZIYYBKO-IBGZPJMESA-N 0.000 description 2
- CMGIBYZPSFPPFJ-UHFFFAOYSA-N 5-[5-[1-(2-hydroxyethylamino)-2,3-dihydro-1h-inden-4-yl]thiophen-2-yl]-2-propan-2-yloxybenzonitrile Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=CC=C(C=2C=3CCC(C=3C=CC=2)NCCO)S1 CMGIBYZPSFPPFJ-UHFFFAOYSA-N 0.000 description 2
- ASSPUGJOKNDEPF-UHFFFAOYSA-N 5-[5-[1-[tert-butyl(dimethyl)silyl]oxy-2,3-dihydro-1h-inden-4-yl]thiophen-2-yl]-2-propan-2-yloxybenzonitrile Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=CC=C(C=2C=3CCC(C=3C=CC=2)O[Si](C)(C)C(C)(C)C)S1 ASSPUGJOKNDEPF-UHFFFAOYSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 208000007788 Acute Liver Failure Diseases 0.000 description 2
- 208000026872 Addison Disease Diseases 0.000 description 2
- 206010001367 Adrenal insufficiency Diseases 0.000 description 2
- 201000010000 Agranulocytosis Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 206010002065 Anaemia megaloblastic Diseases 0.000 description 2
- 208000028185 Angioedema Diseases 0.000 description 2
- 206010002961 Aplasia Diseases 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 2
- 208000023328 Basedow disease Diseases 0.000 description 2
- 208000009137 Behcet syndrome Diseases 0.000 description 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 2
- 240000001546 Byrsonima crassifolia Species 0.000 description 2
- OGJDYFNVBVKXAZ-VWLOTQADSA-N C(C)(C)(C)[Si](OCCN[C@H]1CCC2=C(C=CC=C12)C1=NSC(=N1)C=1C=CC(=C(C#N)C1)OC(C)C)(C)C Chemical compound C(C)(C)(C)[Si](OCCN[C@H]1CCC2=C(C=CC=C12)C1=NSC(=N1)C=1C=CC(=C(C#N)C1)OC(C)C)(C)C OGJDYFNVBVKXAZ-VWLOTQADSA-N 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 208000031229 Cardiomyopathies Diseases 0.000 description 2
- 208000002177 Cataract Diseases 0.000 description 2
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 2
- 208000002691 Choroiditis Diseases 0.000 description 2
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 2
- KBHQWFIBGMJTGM-FERBBOLQSA-N Cl.CC(C)Oc1ccc(cc1C#N)-c1nc(ns1)-c1cccc2[C@@H](N)CCc12 Chemical compound Cl.CC(C)Oc1ccc(cc1C#N)-c1nc(ns1)-c1cccc2[C@@H](N)CCc12 KBHQWFIBGMJTGM-FERBBOLQSA-N 0.000 description 2
- QCHMTJYTBXUBOH-BDQAORGHSA-N Cl.N[C@@H]1C=2C=CC=C(C2CCC1)C1=CN=C(S1)C=1C=CC(=C(C#N)C1)OC(C)C Chemical compound Cl.N[C@@H]1C=2C=CC=C(C2CCC1)C1=CN=C(S1)C=1C=CC(=C(C#N)C1)OC(C)C QCHMTJYTBXUBOH-BDQAORGHSA-N 0.000 description 2
- 206010009657 Clostridium difficile colitis Diseases 0.000 description 2
- 208000015943 Coeliac disease Diseases 0.000 description 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 2
- 102000036530 EDG receptors Human genes 0.000 description 2
- 108091007263 EDG receptors Proteins 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- 206010060742 Endocrine ophthalmopathy Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010014950 Eosinophilia Diseases 0.000 description 2
- 206010014954 Eosinophilic fasciitis Diseases 0.000 description 2
- 206010014989 Epidermolysis bullosa Diseases 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 102000016621 Focal Adhesion Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108010067715 Focal Adhesion Protein-Tyrosine Kinases Proteins 0.000 description 2
- 102000008338 G protein-coupled adenosine receptor activity proteins Human genes 0.000 description 2
- 108040002766 G protein-coupled adenosine receptor activity proteins Proteins 0.000 description 2
- 108091006027 G proteins Proteins 0.000 description 2
- 102000030782 GTP binding Human genes 0.000 description 2
- 108091000058 GTP-Binding Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 2
- 208000024869 Goodpasture syndrome Diseases 0.000 description 2
- 206010018691 Granuloma Diseases 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 2
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- 206010021074 Hypoplastic anaemia Diseases 0.000 description 2
- 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 description 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 208000004852 Lung Injury Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 208000000682 Megaloblastic Anemia Diseases 0.000 description 2
- 208000027530 Meniere disease Diseases 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 238000006845 Michael addition reaction Methods 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 2
- 206010027910 Mononeuritis Diseases 0.000 description 2
- 208000024599 Mooren ulcer Diseases 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000009525 Myocarditis Diseases 0.000 description 2
- OKIZCWYLBDKLSU-UHFFFAOYSA-M N,N,N-Trimethylmethanaminium chloride Chemical compound [Cl-].C[N+](C)(C)C OKIZCWYLBDKLSU-UHFFFAOYSA-M 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 206010051606 Necrotising colitis Diseases 0.000 description 2
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 206010073938 Ophthalmic herpes simplex Diseases 0.000 description 2
- 206010031252 Osteomyelitis Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- 206010034277 Pemphigoid Diseases 0.000 description 2
- 208000031845 Pernicious anaemia Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 206010036105 Polyneuropathy Diseases 0.000 description 2
- 208000003971 Posterior uveitis Diseases 0.000 description 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 2
- 206010036774 Proctitis Diseases 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 description 2
- 206010037128 Pseudomembranous colitis Diseases 0.000 description 2
- 208000006311 Pyoderma Diseases 0.000 description 2
- 206010037779 Radiculopathy Diseases 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 2
- ULFDJZLEEOKIMZ-SFHVURJKSA-N S(=O)(=O)(N[C@H]1CCC2=C(C=CC=C12)C1=NC(=NS1)C1=CC(=C(C=C1)OC(C)C)C#N)N Chemical compound S(=O)(=O)(N[C@H]1CCC2=C(C=CC=C12)C1=NC(=NS1)C1=CC(=C(C=C1)OC(C)C)C#N)N ULFDJZLEEOKIMZ-SFHVURJKSA-N 0.000 description 2
- 241000785681 Sander vitreus Species 0.000 description 2
- 206010039705 Scleritis Diseases 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 208000009359 Sezary Syndrome Diseases 0.000 description 2
- 208000021388 Sezary disease Diseases 0.000 description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102100025747 Sphingosine 1-phosphate receptor 3 Human genes 0.000 description 2
- 101710155457 Sphingosine 1-phosphate receptor 3 Proteins 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 2
- 208000001106 Takayasu Arteritis Diseases 0.000 description 2
- 206010053615 Thermal burn Diseases 0.000 description 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 2
- 206010069363 Traumatic lung injury Diseases 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- 208000001445 Uveomeningoencephalitic Syndrome Diseases 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- 208000034705 Vogt-Koyanagi-Harada syndrome Diseases 0.000 description 2
- CPNJYUJMJOGAMA-AWEZNQCLSA-N [(1s)-4-bromo-2,3-dihydro-1h-inden-1-yl]oxy-tert-butyl-dimethylsilane Chemical compound C1=CC=C(Br)C2=C1[C@@H](O[Si](C)(C)C(C)(C)C)CC2 CPNJYUJMJOGAMA-AWEZNQCLSA-N 0.000 description 2
- VCJWIWDRCVEAOI-UHFFFAOYSA-N [4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-1h-inden-1-yl] carbamate Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=CC2=C1CCC2OC(N)=O VCJWIWDRCVEAOI-UHFFFAOYSA-N 0.000 description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 2
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
- 239000012346 acetyl chloride Substances 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 description 2
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 208000017515 adrenocortical insufficiency Diseases 0.000 description 2
- 206010064930 age-related macular degeneration Diseases 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 201000009961 allergic asthma Diseases 0.000 description 2
- 208000002205 allergic conjunctivitis Diseases 0.000 description 2
- 231100000360 alopecia Toxicity 0.000 description 2
- 208000004631 alopecia areata Diseases 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 150000001409 amidines Chemical class 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 2
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 2
- 125000002393 azetidinyl group Chemical group 0.000 description 2
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- KDPAWGWELVVRCH-UHFFFAOYSA-M bromoacetate Chemical compound [O-]C(=O)CBr KDPAWGWELVVRCH-UHFFFAOYSA-M 0.000 description 2
- ODWXUNBKCRECNW-UHFFFAOYSA-M bromocopper(1+) Chemical compound Br[Cu+] ODWXUNBKCRECNW-UHFFFAOYSA-M 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 208000000594 bullous pemphigoid Diseases 0.000 description 2
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 2
- OWBTYPJTUOEWEK-UHFFFAOYSA-N butane-2,3-diol Chemical compound CC(O)C(C)O OWBTYPJTUOEWEK-UHFFFAOYSA-N 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000004568 cement Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001805 chlorine compounds Chemical class 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 208000010247 contact dermatitis Diseases 0.000 description 2
- 201000007717 corneal ulcer Diseases 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 208000033679 diabetic kidney disease Diseases 0.000 description 2
- ZOCHARZZJNPSEU-UHFFFAOYSA-N diboron Chemical compound B#B ZOCHARZZJNPSEU-UHFFFAOYSA-N 0.000 description 2
- BTVWZWFKMIUSGS-UHFFFAOYSA-N dimethylethyleneglycol Natural products CC(C)(O)CO BTVWZWFKMIUSGS-UHFFFAOYSA-N 0.000 description 2
- UBHZUDXTHNMNLD-UHFFFAOYSA-N dimethylsilane Chemical compound C[SiH2]C UBHZUDXTHNMNLD-UHFFFAOYSA-N 0.000 description 2
- 125000005879 dioxolanyl group Chemical group 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- JOXWSDNHLSQKCC-UHFFFAOYSA-N ethenesulfonamide Chemical compound NS(=O)(=O)C=C JOXWSDNHLSQKCC-UHFFFAOYSA-N 0.000 description 2
- 208000024711 extrinsic asthma Diseases 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 208000007565 gingivitis Diseases 0.000 description 2
- 206010061989 glomerulosclerosis Diseases 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 206010019692 hepatic necrosis Diseases 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 230000003463 hyperproliferative effect Effects 0.000 description 2
- 230000035874 hyperreactivity Effects 0.000 description 2
- 206010021198 ichthyosis Diseases 0.000 description 2
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 2
- 150000002466 imines Chemical class 0.000 description 2
- 229940125721 immunosuppressive agent Drugs 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- 201000006334 interstitial nephritis Diseases 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 201000010659 intrinsic asthma Diseases 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 2
- 201000010666 keratoconjunctivitis Diseases 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 201000010260 leiomyoma Diseases 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 201000011486 lichen planus Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 231100000149 liver necrosis Toxicity 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 231100000515 lung injury Toxicity 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 230000000527 lymphocytic effect Effects 0.000 description 2
- 210000003563 lymphoid tissue Anatomy 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 208000008585 mastocytosis Diseases 0.000 description 2
- 231100001016 megaloblastic anemia Toxicity 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 description 2
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 229940111688 monobasic potassium phosphate Drugs 0.000 description 2
- 208000013734 mononeuritis simplex Diseases 0.000 description 2
- 201000005518 mononeuropathy Diseases 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 201000006938 muscular dystrophy Diseases 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- CXUCCROTKDGWTC-OAQYLSRUSA-N n-[(1r)-4-[2-(3-cyano-4-propan-2-yloxyphenyl)-1,3-thiazol-5-yl]-2,3-dihydro-1h-inden-1-yl]ethenesulfonamide Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NC=C(C=2C=3CC[C@H](C=3C=CC=2)NS(=O)(=O)C=C)S1 CXUCCROTKDGWTC-OAQYLSRUSA-N 0.000 description 2
- PHYXLVBKNLQJFR-HXUWFJFHSA-N n-[(1r)-4-[5-(3-cyano-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-2,3-dihydro-1h-inden-1-yl]ethenesulfonamide Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NN=C(C=2C=3CC[C@H](C=3C=CC=2)NS(=O)(=O)C=C)S1 PHYXLVBKNLQJFR-HXUWFJFHSA-N 0.000 description 2
- UOGRGIANUVKQMW-NRFANRHFSA-N n-[(1s)-4-[2-(3-cyano-4-propan-2-yloxyphenyl)-1,3-thiazol-5-yl]-2,3-dihydro-1h-inden-1-yl]-2-hydroxyethanesulfonamide Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NC=C(C=2C=3CC[C@@H](C=3C=CC=2)NS(=O)(=O)CCO)S1 UOGRGIANUVKQMW-NRFANRHFSA-N 0.000 description 2
- VJCBILWQRVFTGX-NRFANRHFSA-N n-[(1s)-4-[2-(3-cyano-4-propan-2-yloxyphenyl)-1,3-thiazol-5-yl]-2,3-dihydro-1h-inden-1-yl]-2-methoxyacetamide Chemical compound C([C@@H]1NC(=O)COC)CC2=C1C=CC=C2C(S1)=CN=C1C1=CC=C(OC(C)C)C(C#N)=C1 VJCBILWQRVFTGX-NRFANRHFSA-N 0.000 description 2
- WBWONVKVFUKYDJ-IBGZPJMESA-N n-[(1s)-4-[5-(3-cyano-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-2,3-dihydro-1h-inden-1-yl]-2-hydroxyacetamide Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NN=C(C=2C=3CC[C@@H](C=3C=CC=2)NC(=O)CO)S1 WBWONVKVFUKYDJ-IBGZPJMESA-N 0.000 description 2
- XIKKWMLWIBGUQQ-IBGZPJMESA-N n-[(1s)-4-[5-(3-cyano-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-2,3-dihydro-1h-inden-1-yl]methanesulfonamide Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NN=C(C=2C=3CC[C@@H](C=3C=CC=2)NS(C)(=O)=O)S1 XIKKWMLWIBGUQQ-IBGZPJMESA-N 0.000 description 2
- WZNKPBZEBXRJQP-SJCJKPOMSA-N n-[(1s)-4-bromo-2,3-dihydro-1h-inden-1-yl]-2-methylpropane-2-sulfinamide Chemical compound C1=CC=C(Br)C2=C1[C@@H](N[S@@](=O)C(C)(C)C)CC2 WZNKPBZEBXRJQP-SJCJKPOMSA-N 0.000 description 2
- XKPYJOUKOSABHM-FQEVSTJZSA-N n-[(1s)-5-[5-(3-cyano-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-1,2,3,4-tetrahydronaphthalen-1-yl]-2-hydroxyacetamide Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NN=C(C=2C=3CCC[C@@H](C=3C=CC=2)NC(=O)CO)S1 XKPYJOUKOSABHM-FQEVSTJZSA-N 0.000 description 2
- 208000004995 necrotizing enterocolitis Diseases 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 150000002825 nitriles Chemical group 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 230000000414 obstructive effect Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 description 2
- 201000001245 periodontitis Diseases 0.000 description 2
- 210000004261 periodontium Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 description 2
- 201000006292 polyarteritis nodosa Diseases 0.000 description 2
- 208000005987 polymyositis Diseases 0.000 description 2
- 208000019629 polyneuritis Diseases 0.000 description 2
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical group [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000002633 protecting effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 201000003651 pulmonary sarcoidosis Diseases 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 201000000306 sarcoidosis Diseases 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 208000010157 sclerosing cholangitis Diseases 0.000 description 2
- 208000008742 seborrheic dermatitis Diseases 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 208000013223 septicemia Diseases 0.000 description 2
- 230000009919 sequestration Effects 0.000 description 2
- 208000004003 siderosis Diseases 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 125000000565 sulfonamide group Chemical group 0.000 description 2
- 150000003462 sulfoxides Chemical class 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- JBXWXGOHZVNEJY-UHFFFAOYSA-N tert-butyl-dimethyl-[[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-1h-inden-1-yl]oxy]silane Chemical compound CC(C)(C)[Si](C)(C)OC1CCC2=C1C=CC=C2B1OC(C)(C)C(C)(C)O1 JBXWXGOHZVNEJY-UHFFFAOYSA-N 0.000 description 2
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 2
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000036575 thermal burns Effects 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 208000005057 thyrotoxicosis Diseases 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- GOWNSHUNTJWVOM-UHFFFAOYSA-N tributyl(1,3-thiazol-5-yl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C1=CN=CS1 GOWNSHUNTJWVOM-UHFFFAOYSA-N 0.000 description 2
- 230000003966 vascular damage Effects 0.000 description 2
- 201000005539 vernal conjunctivitis Diseases 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical group C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- JTAROQGOUCFPBV-VIFPVBQESA-N (1S)-2,3-dihydro-1H-indene-1-sulfonamide Chemical compound C1=CC=C2[C@@H](S(=O)(=O)N)CCC2=C1 JTAROQGOUCFPBV-VIFPVBQESA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- XJEVHMGJSYVQBQ-VIFPVBQESA-N (1s)-2,3-dihydro-1h-inden-1-amine Chemical compound C1=CC=C2[C@@H](N)CCC2=C1 XJEVHMGJSYVQBQ-VIFPVBQESA-N 0.000 description 1
- MVGZSXVETDUUMZ-VIFPVBQESA-N (1s)-4-bromo-2,3-dihydro-1h-inden-1-amine Chemical compound C1=CC=C(Br)C2=C1[C@@H](N)CC2 MVGZSXVETDUUMZ-VIFPVBQESA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- ZZMYWYZPNZRYPX-SANMLTNESA-N (2r)-2-amino-2-[5-[4-[2-(4-phenylphenyl)ethoxy]-3-(trifluoromethyl)phenyl]-1h-imidazol-2-yl]propan-1-ol Chemical compound N1C([C@@](N)(CO)C)=NC=C1C(C=C1C(F)(F)F)=CC=C1OCCC1=CC=C(C=2C=CC=CC=2)C=C1 ZZMYWYZPNZRYPX-SANMLTNESA-N 0.000 description 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- OLKIYJDSLMKNLC-UHFFFAOYSA-N (3-cyano-4-fluorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(F)C(C#N)=C1 OLKIYJDSLMKNLC-UHFFFAOYSA-N 0.000 description 1
- FNHHVPPSBFQMEL-KQHDFZBMSA-N (3S)-5-N-[(1S,5R)-3-hydroxy-6-bicyclo[3.1.0]hexanyl]-7-N,3-dimethyl-3-phenyl-2H-1-benzofuran-5,7-dicarboxamide Chemical compound CNC(=O)c1cc(cc2c1OC[C@@]2(C)c1ccccc1)C(=O)NC1[C@H]2CC(O)C[C@@H]12 FNHHVPPSBFQMEL-KQHDFZBMSA-N 0.000 description 1
- VMKAFJQFKBASMU-KRWDZBQOSA-N (3as)-1-methyl-3,3-diphenyl-3a,4,5,6-tetrahydropyrrolo[1,2-c][1,3,2]oxazaborole Chemical compound C([C@H]12)CCN1B(C)OC2(C=1C=CC=CC=1)C1=CC=CC=C1 VMKAFJQFKBASMU-KRWDZBQOSA-N 0.000 description 1
- VLECDMDGMKPUSK-NUBCRITNSA-N (3r)-piperidin-3-ol;hydrochloride Chemical compound Cl.O[C@@H]1CCCNC1 VLECDMDGMKPUSK-NUBCRITNSA-N 0.000 description 1
- JHHZLHWJQPUNKB-SCSAIBSYSA-N (3r)-pyrrolidin-3-ol Chemical compound O[C@@H]1CCNC1 JHHZLHWJQPUNKB-SCSAIBSYSA-N 0.000 description 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
- JHHZLHWJQPUNKB-BYPYZUCNSA-N (3s)-pyrrolidin-3-ol Chemical compound O[C@H]1CCNC1 JHHZLHWJQPUNKB-BYPYZUCNSA-N 0.000 description 1
- SJGTWGVKGSVESZ-UHFFFAOYSA-N (4-bromo-2,3-dihydro-1H-inden-1-yl)carbamic acid Chemical compound C1=CC=C(Br)C2=C1C(NC(=O)O)CC2 SJGTWGVKGSVESZ-UHFFFAOYSA-N 0.000 description 1
- CPNJYUJMJOGAMA-UHFFFAOYSA-N (4-bromo-2,3-dihydro-1h-inden-1-yl)oxy-tert-butyl-dimethylsilane Chemical compound C1=CC=C(Br)C2=C1C(O[Si](C)(C)C(C)(C)C)CC2 CPNJYUJMJOGAMA-UHFFFAOYSA-N 0.000 description 1
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
- GHHOTNZAUWEDEV-OKACTXMXSA-N (ne)-n-(4-bromo-2,3-dihydroinden-1-ylidene)-2-methylpropane-2-sulfinamide Chemical compound C1=CC=C(Br)C2=C1C(=N/[S@](=O)C(C)(C)C)/CC2 GHHOTNZAUWEDEV-OKACTXMXSA-N 0.000 description 1
- DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 description 1
- DJAPPXDESPCHNL-UHFFFAOYSA-N 1,2,3,4-tetrahydronaphthalene;1,3,4-thiadiazole Chemical compound C1=NN=CS1.C1=CC=C2CCCCC2=C1 DJAPPXDESPCHNL-UHFFFAOYSA-N 0.000 description 1
- 125000001305 1,2,4-triazol-3-yl group Chemical group [H]N1N=C([*])N=C1[H] 0.000 description 1
- 125000004521 1,3,4-thiadiazol-2-yl group Chemical group S1C(=NN=C1)* 0.000 description 1
- MBIZXFATKUQOOA-UHFFFAOYSA-N 1,3,4-thiadiazole Chemical group C1=NN=CS1 MBIZXFATKUQOOA-UHFFFAOYSA-N 0.000 description 1
- YJTKZCDBKVTVBY-UHFFFAOYSA-N 1,3-Diphenylbenzene Chemical group C1=CC=CC=C1C1=CC=CC(C=2C=CC=CC=2)=C1 YJTKZCDBKVTVBY-UHFFFAOYSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- 125000004173 1-benzimidazolyl group Chemical group [H]C1=NC2=C([H])C([H])=C([H])C([H])=C2N1* 0.000 description 1
- VMKAFJQFKBASMU-UHFFFAOYSA-N 1-methyl-3,3-diphenyl-3a,4,5,6-tetrahydropyrrolo[1,2-c][1,3,2]oxazaborole Chemical compound C12CCCN2B(C)OC1(C=1C=CC=CC=1)C1=CC=CC=C1 VMKAFJQFKBASMU-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- QUBIUECSHYHMOK-UHFFFAOYSA-N 2,3-dihydro-1h-indene;hydrazine Chemical class NN.C1=CC=C2CCCC2=C1 QUBIUECSHYHMOK-UHFFFAOYSA-N 0.000 description 1
- UCQAIBLQFFRESL-UHFFFAOYSA-N 2,3-dihydro-1h-indene;oxadiazole Chemical group C1=CON=N1.C1=CC=C2CCCC2=C1 UCQAIBLQFFRESL-UHFFFAOYSA-N 0.000 description 1
- OFZMOQOOTWYMOU-GOSISDBHSA-N 2-(3-cyano-4-propan-2-yloxyphenyl)-5-[(1r)-1-(sulfamoylamino)-2,3-dihydro-1h-inden-4-yl]-1,3,4-thiadiazole Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NN=C(C=2C=3CC[C@H](C=3C=CC=2)NS(N)(=O)=O)S1 OFZMOQOOTWYMOU-GOSISDBHSA-N 0.000 description 1
- QGPSKHKXNLIWNQ-IBGZPJMESA-N 2-(3-cyano-4-propan-2-yloxyphenyl)-5-[(1s)-1-(sulfamoylamino)-2,3-dihydro-1h-inden-4-yl]-1,3-thiazole Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NC=C(C=2C=3CC[C@@H](C=3C=CC=2)NS(N)(=O)=O)S1 QGPSKHKXNLIWNQ-IBGZPJMESA-N 0.000 description 1
- PHIWQEUBOFTDEN-HXUWFJFHSA-N 2-(3-cyano-4-propan-2-yloxyphenyl)-5-[(5r)-5-(sulfamoylamino)-5,6,7,8-tetrahydronaphthalen-1-yl]-1,3-thiazole Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NC=C(C=2C=3CCC[C@H](C=3C=CC=2)NS(N)(=O)=O)S1 PHIWQEUBOFTDEN-HXUWFJFHSA-N 0.000 description 1
- MZOUSYJVPWNFPQ-HSZRJFAPSA-N 2-[[(1r)-4-[2-(3-cyano-4-propan-2-yloxyphenyl)-1,3-thiazol-5-yl]-2,3-dihydro-1h-inden-1-yl]-[(2-methylpropan-2-yl)oxycarbonyl]amino]acetic acid Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NC=C(C=2C=3CC[C@H](C=3C=CC=2)N(CC(O)=O)C(=O)OC(C)(C)C)S1 MZOUSYJVPWNFPQ-HSZRJFAPSA-N 0.000 description 1
- PDHJOJDTKNNIAL-HXUWFJFHSA-N 2-[[(1r)-4-[2-(3-cyano-4-propan-2-yloxyphenyl)-1,3-thiazol-5-yl]-2,3-dihydro-1h-inden-1-yl]amino]acetic acid Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NC=C(C=2C=3CC[C@H](C=3C=CC=2)NCC(O)=O)S1 PDHJOJDTKNNIAL-HXUWFJFHSA-N 0.000 description 1
- VPWGVDWUCBXEJW-LJQANCHMSA-N 2-[[(1r)-4-[5-(3-cyano-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-2,3-dihydro-1h-inden-1-yl]amino]acetic acid Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NN=C(C=2C=3CC[C@H](C=3C=CC=2)NCC(O)=O)S1 VPWGVDWUCBXEJW-LJQANCHMSA-N 0.000 description 1
- IGIBRXLXADVIOZ-HXUWFJFHSA-N 2-[[(1r)-5-[5-(3-cyano-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-1,2,3,4-tetrahydronaphthalen-1-yl]amino]acetic acid Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NN=C(C=2C=3CCC[C@H](C=3C=CC=2)NCC(O)=O)S1 IGIBRXLXADVIOZ-HXUWFJFHSA-N 0.000 description 1
- KBHLZUFINMMQNB-JOCHJYFZSA-N 2-[[(1r)-5-[5-(3-cyano-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-1,2,3,4-tetrahydronaphthalen-1-yl]sulfamoyl]-n,n-dimethylacetamide Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NN=C(C=2C=3CCC[C@H](C=3C=CC=2)NS(=O)(=O)CC(=O)N(C)C)S1 KBHLZUFINMMQNB-JOCHJYFZSA-N 0.000 description 1
- PDHJOJDTKNNIAL-FQEVSTJZSA-N 2-[[(1s)-4-[2-(3-cyano-4-propan-2-yloxyphenyl)-1,3-thiazol-5-yl]-2,3-dihydro-1h-inden-1-yl]amino]acetic acid Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NC=C(C=2C=3CC[C@@H](C=3C=CC=2)NCC(O)=O)S1 PDHJOJDTKNNIAL-FQEVSTJZSA-N 0.000 description 1
- BZQMSELGQJZXEP-FQEVSTJZSA-N 2-[[(1s)-4-[2-(3-cyano-4-propan-2-yloxyphenyl)-1,3-thiazol-5-yl]-2,3-dihydro-1h-inden-1-yl]sulfamoyl]acetic acid Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NC=C(C=2C=3CC[C@@H](C=3C=CC=2)NS(=O)(=O)CC(O)=O)S1 BZQMSELGQJZXEP-FQEVSTJZSA-N 0.000 description 1
- HALMTUOSENSZJD-NRFANRHFSA-N 2-[[(1s)-4-[5-(3-cyano-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-2,3-dihydro-1h-inden-1-yl]amino]-n,n-dimethylacetamide Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NN=C(C=2C=3CC[C@@H](C=3C=CC=2)NCC(=O)N(C)C)S1 HALMTUOSENSZJD-NRFANRHFSA-N 0.000 description 1
- VPWGVDWUCBXEJW-IBGZPJMESA-N 2-[[(1s)-4-[5-(3-cyano-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-2,3-dihydro-1h-inden-1-yl]amino]acetic acid Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NN=C(C=2C=3CC[C@@H](C=3C=CC=2)NCC(O)=O)S1 VPWGVDWUCBXEJW-IBGZPJMESA-N 0.000 description 1
- LBVMDDWIJRAABB-NRFANRHFSA-N 2-[[(1s)-4-[5-(3-cyano-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-2,3-dihydro-1h-inden-1-yl]sulfamoyl]-n,n-dimethylacetamide Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NN=C(C=2C=3CC[C@@H](C=3C=CC=2)NS(=O)(=O)CC(=O)N(C)C)S1 LBVMDDWIJRAABB-NRFANRHFSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- LVCHXPHUKPLVRQ-UHFFFAOYSA-N 2-bromo-n,n-dimethylethanamine Chemical compound CN(C)CCBr LVCHXPHUKPLVRQ-UHFFFAOYSA-N 0.000 description 1
- MOFRJTLODZILCR-UHFFFAOYSA-N 2-fluoro-5-formylbenzonitrile Chemical compound FC1=CC=C(C=O)C=C1C#N MOFRJTLODZILCR-UHFFFAOYSA-N 0.000 description 1
- BIZHQRAAZMDWNK-UHFFFAOYSA-N 2-fluoro-5-iodobenzonitrile Chemical compound FC1=CC=C(I)C=C1C#N BIZHQRAAZMDWNK-UHFFFAOYSA-N 0.000 description 1
- GDHXJNRAJRCGMX-UHFFFAOYSA-N 2-fluorobenzonitrile Chemical compound FC1=CC=CC=C1C#N GDHXJNRAJRCGMX-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- DUNNNVSEUCJEOY-UHFFFAOYSA-N 2-methoxyethanesulfonyl chloride Chemical compound COCCS(Cl)(=O)=O DUNNNVSEUCJEOY-UHFFFAOYSA-N 0.000 description 1
- ZRNSSRODJSSVEJ-UHFFFAOYSA-N 2-methylpentacosane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC(C)C ZRNSSRODJSSVEJ-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- YFOYJNBGVJBDCW-RUZDIDTESA-N 2-propan-2-yloxy-5-[5-[(5r)-5-(pyridin-3-ylmethylamino)-5,6,7,8-tetrahydronaphthalen-1-yl]-1,3,4-thiadiazol-2-yl]benzonitrile Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NN=C(C=2C=3CCC[C@H](C=3C=CC=2)NCC=2C=NC=CC=2)S1 YFOYJNBGVJBDCW-RUZDIDTESA-N 0.000 description 1
- MSFGJJZPHGNGCY-UHFFFAOYSA-N 2-propan-2-yloxybenzonitrile Chemical compound CC(C)OC1=CC=CC=C1C#N MSFGJJZPHGNGCY-UHFFFAOYSA-N 0.000 description 1
- COQNSVIPYPUWSV-UHFFFAOYSA-N 2-propan-2-yloxybenzonitrile;hydrochloride Chemical compound Cl.CC(C)OC1=CC=CC=C1C#N COQNSVIPYPUWSV-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- DRXQLMRNBKNBEG-QFIPXVFZSA-N 3-[[(1s)-5-[5-(3-cyano-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-1,2,3,4-tetrahydronaphthalen-1-yl]sulfamoyl]-n-methylpropanamide Chemical compound C([C@@H]1NS(=O)(=O)CCC(=O)NC)CCC2=C1C=CC=C2C(S1)=NN=C1C1=CC=C(OC(C)C)C(C#N)=C1 DRXQLMRNBKNBEG-QFIPXVFZSA-N 0.000 description 1
- CXUWGEWQRCXJDC-UHFFFAOYSA-N 3-bromo-5-chloro-1,2,4-thiadiazole Chemical compound ClC1=NC(Br)=NS1 CXUWGEWQRCXJDC-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- MPMKMQHJHDHPBE-RUZDIDTESA-N 4-[[(2r)-1-(1-benzothiophene-3-carbonyl)-2-methylazetidine-2-carbonyl]-[(3-chlorophenyl)methyl]amino]butanoic acid Chemical compound O=C([C@@]1(N(CC1)C(=O)C=1C2=CC=CC=C2SC=1)C)N(CCCC(O)=O)CC1=CC=CC(Cl)=C1 MPMKMQHJHDHPBE-RUZDIDTESA-N 0.000 description 1
- XWQVQSXLXAXOPJ-QNGMFEMESA-N 4-[[[6-[5-chloro-2-[[4-[[(2r)-1-methoxypropan-2-yl]amino]cyclohexyl]amino]pyridin-4-yl]pyridin-2-yl]amino]methyl]oxane-4-carbonitrile Chemical compound C1CC(N[C@H](C)COC)CCC1NC1=CC(C=2N=C(NCC3(CCOCC3)C#N)C=CC=2)=C(Cl)C=N1 XWQVQSXLXAXOPJ-QNGMFEMESA-N 0.000 description 1
- QCXJEYYXVJIFCE-UHFFFAOYSA-M 4-acetamidobenzoate Chemical compound CC(=O)NC1=CC=C(C([O-])=O)C=C1 QCXJEYYXVJIFCE-UHFFFAOYSA-M 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- RNXQQZNOSYBFTN-UHFFFAOYSA-N 4-bromo-2,3-dihydro-1h-inden-1-ol Chemical compound C1=CC=C(Br)C2=C1C(O)CC2 RNXQQZNOSYBFTN-UHFFFAOYSA-N 0.000 description 1
- 125000005274 4-hydroxybenzoic acid group Chemical group 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- LMIUOMGYFMXQPY-VZYDHVRKSA-N 5-[3-[(1r)-1-[bis(2-hydroxyethyl)amino]-2,3-dihydro-1h-inden-4-yl]-1,2,4-thiadiazol-5-yl]-2-propan-2-yloxybenzonitrile;hydrochloride Chemical compound Cl.C1=C(C#N)C(OC(C)C)=CC=C1C1=NC(C=2C=3CC[C@H](C=3C=CC=2)N(CCO)CCO)=NS1 LMIUOMGYFMXQPY-VZYDHVRKSA-N 0.000 description 1
- AWOMQWTXBCOFDO-UHFFFAOYSA-N 5-[5-(1-hydroxy-2,3-dihydro-1h-inden-4-yl)-1,3-thiazol-2-yl]-2-propan-2-yloxybenzonitrile Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NC=C(C=2C=3CCC(O)C=3C=CC=2)S1 AWOMQWTXBCOFDO-UHFFFAOYSA-N 0.000 description 1
- SLBZWCIZOVUOFZ-JOCHJYFZSA-N 5-[5-[(1R)-1-[tert-butyl(dimethyl)silyl]oxy-1H-inden-4-yl]-1,3-thiazol-2-yl]-2-fluorobenzonitrile Chemical compound [Si](C)(C)(C(C)(C)C)O[C@@H]1C=CC2=C(C=CC=C12)C1=CN=C(S1)C=1C=CC(=C(C#N)C=1)F SLBZWCIZOVUOFZ-JOCHJYFZSA-N 0.000 description 1
- QMTJBVPEPUIHRS-OAQYLSRUSA-N 5-[5-[(1r)-1-(1h-imidazol-2-ylmethylamino)-2,3-dihydro-1h-inden-4-yl]-1,3,4-thiadiazol-2-yl]-2-propan-2-yloxybenzonitrile Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NN=C(C=2C=3CC[C@H](C=3C=CC=2)NCC=2NC=CN=2)S1 QMTJBVPEPUIHRS-OAQYLSRUSA-N 0.000 description 1
- ZNINXPXWDFBZBP-OAQYLSRUSA-N 5-[5-[(1r)-1-(2-hydroxyethylamino)-2,3-dihydro-1h-inden-4-yl]-1,3-thiazol-2-yl]-2-propan-2-yloxybenzonitrile Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NC=C(C=2C=3CC[C@H](C=3C=CC=2)NCCO)S1 ZNINXPXWDFBZBP-OAQYLSRUSA-N 0.000 description 1
- FDEXCIIJHWGQQX-RUZDIDTESA-N 5-[5-[(1r)-1-[2-[tert-butyl(dimethyl)silyl]oxyethylamino]-2,3-dihydro-1h-inden-4-yl]-1,3,4-thiadiazol-2-yl]-2-propan-2-yloxybenzonitrile Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NN=C(C=2C=3CC[C@H](C=3C=CC=2)NCCO[Si](C)(C)C(C)(C)C)S1 FDEXCIIJHWGQQX-RUZDIDTESA-N 0.000 description 1
- BXDVXJDPGZLVSK-OAQYLSRUSA-N 5-[5-[(1r)-1-[tert-butyl(dimethyl)silyl]oxy-2,3-dihydro-1h-inden-4-yl]-1,3,4-thiadiazol-2-yl]-2-fluorobenzonitrile Chemical compound C([C@H]1O[Si](C)(C)C(C)(C)C)CC2=C1C=CC=C2C(S1)=NN=C1C1=CC=C(F)C(C#N)=C1 BXDVXJDPGZLVSK-OAQYLSRUSA-N 0.000 description 1
- YIDAVWGHLSRPLC-XMMPIXPASA-N 5-[5-[(1r)-1-[tert-butyl(dimethyl)silyl]oxy-2,3-dihydro-1h-inden-4-yl]-1,3,4-thiadiazol-2-yl]-2-propan-2-yloxybenzonitrile Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NN=C(C=2C=3CC[C@H](C=3C=CC=2)O[Si](C)(C)C(C)(C)C)S1 YIDAVWGHLSRPLC-XMMPIXPASA-N 0.000 description 1
- OAHRZAAPKIARIZ-JOCHJYFZSA-N 5-[5-[(1r)-1-[tert-butyl(dimethyl)silyl]oxy-2,3-dihydro-1h-inden-4-yl]-1,3-thiazol-2-yl]-2-fluorobenzonitrile Chemical compound C([C@H]1O[Si](C)(C)C(C)(C)C)CC2=C1C=CC=C2C(S1)=CN=C1C1=CC=C(F)C(C#N)=C1 OAHRZAAPKIARIZ-JOCHJYFZSA-N 0.000 description 1
- DMPGODYTHQFFSN-GOSISDBHSA-N 5-[5-[(1r)-1-amino-2,3-dihydro-1h-inden-4-yl]-1,3,4-thiadiazol-2-yl]-2-propan-2-yloxybenzonitrile Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NN=C(C=2C=3CC[C@@H](N)C=3C=CC=2)S1 DMPGODYTHQFFSN-GOSISDBHSA-N 0.000 description 1
- FPJWIJWMNQLJQF-LJQANCHMSA-N 5-[5-[(1r)-1-amino-2,3-dihydro-1h-inden-4-yl]-1,3-thiazol-2-yl]-2-propan-2-yloxybenzonitrile Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NC=C(C=2C=3CC[C@@H](N)C=3C=CC=2)S1 FPJWIJWMNQLJQF-LJQANCHMSA-N 0.000 description 1
- KUTKPORHNXZOFO-HXUWFJFHSA-N 5-[5-[(1r)-1-amino-2,3-dihydro-1h-inden-4-yl]thiophen-2-yl]-2-propan-2-yloxybenzonitrile Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=CC=C(C=2C=3CC[C@@H](N)C=3C=CC=2)S1 KUTKPORHNXZOFO-HXUWFJFHSA-N 0.000 description 1
- ZWCYSYVUEOYJOJ-GOSISDBHSA-N 5-[5-[(1r)-1-hydroxy-2,3-dihydro-1h-inden-4-yl]-1,3,4-thiadiazol-2-yl]-2-propan-2-yloxybenzonitrile Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NN=C(C=2C=3CC[C@@H](O)C=3C=CC=2)S1 ZWCYSYVUEOYJOJ-GOSISDBHSA-N 0.000 description 1
- AWOMQWTXBCOFDO-LJQANCHMSA-N 5-[5-[(1r)-1-hydroxy-2,3-dihydro-1h-inden-4-yl]-1,3-thiazol-2-yl]-2-propan-2-yloxybenzonitrile Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NC=C(C=2C=3CC[C@@H](O)C=3C=CC=2)S1 AWOMQWTXBCOFDO-LJQANCHMSA-N 0.000 description 1
- VYFNLOWSXLCRFM-FQEVSTJZSA-N 5-[5-[(1s)-1-(2-hydroxyethylamino)-2,3-dihydro-1h-inden-4-yl]-1,3,4-thiadiazol-2-yl]-2-propan-2-yloxybenzonitrile Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NN=C(C=2C=3CC[C@@H](C=3C=CC=2)NCCO)S1 VYFNLOWSXLCRFM-FQEVSTJZSA-N 0.000 description 1
- RGMNRZVRAKMLLO-NRFANRHFSA-N 5-[5-[(1s)-1-(2-methylsulfonylethylamino)-2,3-dihydro-1h-inden-4-yl]-1,3,4-thiadiazol-2-yl]-2-propan-2-yloxybenzonitrile Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NN=C(C=2C=3CC[C@@H](C=3C=CC=2)NCCS(C)(=O)=O)S1 RGMNRZVRAKMLLO-NRFANRHFSA-N 0.000 description 1
- WPYMCLGKBISIPD-QFIPXVFZSA-N 5-[5-[(1s)-1-(2-methylsulfonylethylamino)-2,3-dihydro-1h-inden-4-yl]-1,3-thiazol-2-yl]-2-propan-2-yloxybenzonitrile Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NC=C(C=2C=3CC[C@@H](C=3C=CC=2)NCCS(C)(=O)=O)S1 WPYMCLGKBISIPD-QFIPXVFZSA-N 0.000 description 1
- FDEXCIIJHWGQQX-VWLOTQADSA-N 5-[5-[(1s)-1-[2-[tert-butyl(dimethyl)silyl]oxyethylamino]-2,3-dihydro-1h-inden-4-yl]-1,3,4-thiadiazol-2-yl]-2-propan-2-yloxybenzonitrile Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NN=C(C=2C=3CC[C@@H](C=3C=CC=2)NCCO[Si](C)(C)C(C)(C)C)S1 FDEXCIIJHWGQQX-VWLOTQADSA-N 0.000 description 1
- OAHRZAAPKIARIZ-QFIPXVFZSA-N 5-[5-[(1s)-1-[tert-butyl(dimethyl)silyl]oxy-2,3-dihydro-1h-inden-4-yl]-1,3-thiazol-2-yl]-2-fluorobenzonitrile Chemical compound C([C@@H]1O[Si](C)(C)C(C)(C)C)CC2=C1C=CC=C2C(S1)=CN=C1C1=CC=C(F)C(C#N)=C1 OAHRZAAPKIARIZ-QFIPXVFZSA-N 0.000 description 1
- UEOBSCOQKGKHHG-VWLOTQADSA-N 5-[5-[(1s)-1-[tert-butyl(dimethyl)silyl]oxy-2,3-dihydro-1h-inden-4-yl]-1,3-thiazol-2-yl]-2-propan-2-yloxybenzonitrile Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NC=C(C=2C=3CC[C@@H](C=3C=CC=2)O[Si](C)(C)C(C)(C)C)S1 UEOBSCOQKGKHHG-VWLOTQADSA-N 0.000 description 1
- DMPGODYTHQFFSN-SFHVURJKSA-N 5-[5-[(1s)-1-amino-2,3-dihydro-1h-inden-4-yl]-1,3,4-thiadiazol-2-yl]-2-propan-2-yloxybenzonitrile Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NN=C(C=2C=3CC[C@H](N)C=3C=CC=2)S1 DMPGODYTHQFFSN-SFHVURJKSA-N 0.000 description 1
- NHFKYRYFDXPBDR-FERBBOLQSA-N 5-[5-[(1s)-1-amino-2,3-dihydro-1h-inden-4-yl]-1,3,4-thiadiazol-2-yl]-2-propan-2-yloxybenzonitrile;hydrochloride Chemical compound Cl.C1=C(C#N)C(OC(C)C)=CC=C1C1=NN=C(C=2C=3CC[C@H](N)C=3C=CC=2)S1 NHFKYRYFDXPBDR-FERBBOLQSA-N 0.000 description 1
- ZWCYSYVUEOYJOJ-SFHVURJKSA-N 5-[5-[(1s)-1-hydroxy-2,3-dihydro-1h-inden-4-yl]-1,3,4-thiadiazol-2-yl]-2-propan-2-yloxybenzonitrile Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NN=C(C=2C=3CC[C@H](O)C=3C=CC=2)S1 ZWCYSYVUEOYJOJ-SFHVURJKSA-N 0.000 description 1
- JZSVOSHKJDKLIQ-OAQYLSRUSA-N 5-[5-[(5r)-5-(2-hydroxyethylamino)-5,6,7,8-tetrahydronaphthalen-1-yl]-1,3,4-thiadiazol-2-yl]-2-propan-2-yloxybenzonitrile Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NN=C(C=2C=3CCC[C@H](C=3C=CC=2)NCCO)S1 JZSVOSHKJDKLIQ-OAQYLSRUSA-N 0.000 description 1
- ZLPXDGHQUNHTFN-XMMPIXPASA-N 5-[5-[(5r)-5-[(2-oxo-2-pyrrolidin-1-ylethyl)amino]-5,6,7,8-tetrahydronaphthalen-1-yl]-1,3,4-thiadiazol-2-yl]-2-propan-2-yloxybenzonitrile Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NN=C(C=2C=3CCC[C@H](C=3C=CC=2)NCC(=O)N2CCCC2)S1 ZLPXDGHQUNHTFN-XMMPIXPASA-N 0.000 description 1
- URGDNXTUTVCKGL-UHFFFAOYSA-N 5-[5-[1-[tert-butyl(dimethyl)silyl]oxy-2,3-dihydro-1h-inden-4-yl]thiophen-3-yl]-2-propan-2-yloxybenzonitrile Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=CSC(C=2C=3CCC(C=3C=CC=2)O[Si](C)(C)C(C)(C)C)=C1 URGDNXTUTVCKGL-UHFFFAOYSA-N 0.000 description 1
- 125000004539 5-benzimidazolyl group Chemical group N1=CNC2=C1C=CC(=C2)* 0.000 description 1
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 1
- IJRKLHTZAIFUTB-UHFFFAOYSA-N 5-nitro-2-(2-phenylethylamino)benzoic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=CC=C1NCCC1=CC=CC=C1 IJRKLHTZAIFUTB-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- LCGTWRLJTMHIQZ-UHFFFAOYSA-N 5H-dibenzo[b,f]azepine Chemical compound C1=CC2=CC=CC=C2NC2=CC=CC=C21 LCGTWRLJTMHIQZ-UHFFFAOYSA-N 0.000 description 1
- ZSMRRZONCYIFNB-UHFFFAOYSA-N 6,11-dihydro-5h-benzo[b][1]benzazepine Chemical compound C1CC2=CC=CC=C2NC2=CC=CC=C12 ZSMRRZONCYIFNB-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- NJIAKNWTIVDSDA-FQEVSTJZSA-N 7-[4-(1-methylsulfonylpiperidin-4-yl)phenyl]-n-[[(2s)-morpholin-2-yl]methyl]pyrido[3,4-b]pyrazin-5-amine Chemical compound C1CN(S(=O)(=O)C)CCC1C1=CC=C(C=2N=C(NC[C@H]3OCCNC3)C3=NC=CN=C3C=2)C=C1 NJIAKNWTIVDSDA-FQEVSTJZSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- UDKDVOVOZAFTMN-FQEVSTJZSA-N C(#N)C=1C=C(C=CC1OC(C)C)C1=NN=C(S1)C1=C2CCC[C@@H](C2=CC=C1)NS(=O)(=O)CC(=O)O Chemical compound C(#N)C=1C=C(C=CC1OC(C)C)C1=NN=C(S1)C1=C2CCC[C@@H](C2=CC=C1)NS(=O)(=O)CC(=O)O UDKDVOVOZAFTMN-FQEVSTJZSA-N 0.000 description 1
- DRXQLMRNBKNBEG-JOCHJYFZSA-N C(#N)C=1C=C(C=CC=1OC(C)C)C1=NN=C(S1)C1=C2CCC[C@H](C2=CC=C1)NS(=O)(=O)CCC(=O)NC Chemical compound C(#N)C=1C=C(C=CC=1OC(C)C)C1=NN=C(S1)C1=C2CCC[C@H](C2=CC=C1)NS(=O)(=O)CCC(=O)NC DRXQLMRNBKNBEG-JOCHJYFZSA-N 0.000 description 1
- PHIWQEUBOFTDEN-FQEVSTJZSA-N C(#N)C=1C=C(C=CC=1OC(C)C)C=1SC(=CN=1)C1=C2CCC[C@@H](C2=CC=C1)NS(=O)(=O)N Chemical compound C(#N)C=1C=C(C=CC=1OC(C)C)C=1SC(=CN=1)C1=C2CCC[C@@H](C2=CC=C1)NS(=O)(=O)N PHIWQEUBOFTDEN-FQEVSTJZSA-N 0.000 description 1
- OGJDYFNVBVKXAZ-RUZDIDTESA-N C(C)(C)(C)[Si](OCCN[C@@H]1CCC2=C(C=CC=C12)C1=NSC(=N1)C=1C=CC(=C(C#N)C1)OC(C)C)(C)C Chemical compound C(C)(C)(C)[Si](OCCN[C@@H]1CCC2=C(C=CC=C12)C1=NSC(=N1)C=1C=CC(=C(C#N)C1)OC(C)C)(C)C OGJDYFNVBVKXAZ-RUZDIDTESA-N 0.000 description 1
- UNQQFLILYQEXIQ-JOCHJYFZSA-N C(C)(C)OC1=C(C#N)C=C(C=C1)C=1SC(=NN1)C1=CC=CC=2[C@@H](CCCC12)NCCS(=O)(=O)C Chemical compound C(C)(C)OC1=C(C#N)C=C(C=C1)C=1SC(=NN1)C1=CC=CC=2[C@@H](CCCC12)NCCS(=O)(=O)C UNQQFLILYQEXIQ-JOCHJYFZSA-N 0.000 description 1
- ZLPXDGHQUNHTFN-DEOSSOPVSA-N C(C)(C)OC1=C(C#N)C=C(C=C1)C=1SC(=NN=1)C1=CC=CC=2[C@H](CCCC1=2)NCC(N1CCCC1)=O Chemical compound C(C)(C)OC1=C(C#N)C=C(C=C1)C=1SC(=NN=1)C1=CC=CC=2[C@H](CCCC1=2)NCC(N1CCCC1)=O ZLPXDGHQUNHTFN-DEOSSOPVSA-N 0.000 description 1
- UNQQFLILYQEXIQ-QFIPXVFZSA-N C(C)(C)OC1=C(C#N)C=C(C=C1)C=1SC(=NN=1)C1=CC=CC=2[C@H](CCCC1=2)NCCS(=O)(=O)C Chemical compound C(C)(C)OC1=C(C#N)C=C(C=C1)C=1SC(=NN=1)C1=CC=CC=2[C@H](CCCC1=2)NCCS(=O)(=O)C UNQQFLILYQEXIQ-QFIPXVFZSA-N 0.000 description 1
- MPFFHJYBYROHDD-UHFFFAOYSA-N C(N)(OC1CCC2=C(C=CC=C12)C1=NSC(=N1)C1=CC(=C(C=C1)OC(C)C)C#N)=O Chemical compound C(N)(OC1CCC2=C(C=CC=C12)C1=NSC(=N1)C1=CC(=C(C=C1)OC(C)C)C#N)=O MPFFHJYBYROHDD-UHFFFAOYSA-N 0.000 description 1
- XKPYJOUKOSABHM-HXUWFJFHSA-N CC(C)Oc1ccc(cc1C#N)-c1nnc(s1)-c1cccc2[C@@H](CCCc12)NC(=O)CO Chemical compound CC(C)Oc1ccc(cc1C#N)-c1nnc(s1)-c1cccc2[C@@H](CCCc12)NC(=O)CO XKPYJOUKOSABHM-HXUWFJFHSA-N 0.000 description 1
- BLRWNFVDGFCRFL-HXUWFJFHSA-N CC(C)Oc1ccc(cc1C#N)-c1nnc(s1)-c1cccc2[C@@H](CCCc12)NS(C)(=O)=O Chemical compound CC(C)Oc1ccc(cc1C#N)-c1nnc(s1)-c1cccc2[C@@H](CCCc12)NS(C)(=O)=O BLRWNFVDGFCRFL-HXUWFJFHSA-N 0.000 description 1
- IGIBRXLXADVIOZ-FQEVSTJZSA-N CC(C)Oc1ccc(cc1C#N)-c1nnc(s1)-c1cccc2[C@H](CCCc12)NCC(O)=O Chemical compound CC(C)Oc1ccc(cc1C#N)-c1nnc(s1)-c1cccc2[C@H](CCCc12)NCC(O)=O IGIBRXLXADVIOZ-FQEVSTJZSA-N 0.000 description 1
- BLRWNFVDGFCRFL-FQEVSTJZSA-N CC(C)Oc1ccc(cc1C#N)-c1nnc(s1)-c1cccc2[C@H](CCCc12)NS(C)(=O)=O Chemical compound CC(C)Oc1ccc(cc1C#N)-c1nnc(s1)-c1cccc2[C@H](CCCc12)NS(C)(=O)=O BLRWNFVDGFCRFL-FQEVSTJZSA-N 0.000 description 1
- SNQUHNMBSKWPPN-QHCPKHFHSA-N CN(CCN[C@@H]1C=2C=CC=C(C=2CCC1)C1=NN=C(S1)C=1C=CC(=C(C#N)C=1)OC(C)C)C Chemical compound CN(CCN[C@@H]1C=2C=CC=C(C=2CCC1)C1=NN=C(S1)C=1C=CC(=C(C#N)C=1)OC(C)C)C SNQUHNMBSKWPPN-QHCPKHFHSA-N 0.000 description 1
- MSMYZSBFDJFMDW-QFIPXVFZSA-N COCCS(=O)(=O)N[C@H]1CCCc2c1cccc2-c1nnc(s1)-c1ccc(OC(C)C)c(c1)C#N Chemical compound COCCS(=O)(=O)N[C@H]1CCCc2c1cccc2-c1nnc(s1)-c1ccc(OC(C)C)c(c1)C#N MSMYZSBFDJFMDW-QFIPXVFZSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008748 Chorea Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- QCHMTJYTBXUBOH-VEIFNGETSA-N Cl.CC(C)Oc1ccc(cc1C#N)-c1ncc(s1)-c1cccc2[C@H](N)CCCc12 Chemical compound Cl.CC(C)Oc1ccc(cc1C#N)-c1ncc(s1)-c1cccc2[C@H](N)CCCc12 QCHMTJYTBXUBOH-VEIFNGETSA-N 0.000 description 1
- ZUGKGRKDVSIGFR-FSRHSHDFSA-N Cl.CC(C)Oc1ccc(cc1C#N)-c1nnc(s1)-c1cccc2[C@H](N)CCCc12 Chemical compound Cl.CC(C)Oc1ccc(cc1C#N)-c1nnc(s1)-c1cccc2[C@H](N)CCCc12 ZUGKGRKDVSIGFR-FSRHSHDFSA-N 0.000 description 1
- HZDWXOVDJKIEMR-GMUIIQOCSA-N Cl.N[C@@H]1CCC2=C(C=CC=C12)C1=NC(=NS1)C=1C=CC(=C(C#N)C1)OC(C)C Chemical compound Cl.N[C@@H]1CCC2=C(C=CC=C12)C1=NC(=NS1)C=1C=CC(=C(C#N)C1)OC(C)C HZDWXOVDJKIEMR-GMUIIQOCSA-N 0.000 description 1
- ZRHZQHWMFGHBCU-BDQAORGHSA-N Cl.OCCN[C@H]1CCC2=C(C=CC=C12)C1=NSC(=N1)C=1C=CC(=C(C#N)C1)OC(C)C Chemical compound Cl.OCCN[C@H]1CCC2=C(C=CC=C12)C1=NSC(=N1)C=1C=CC(=C(C#N)C1)OC(C)C ZRHZQHWMFGHBCU-BDQAORGHSA-N 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- 102100034741 Cyclin-dependent kinase 20 Human genes 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical group NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 206010017918 Gastroenteritis viral Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 208000005100 Herpetic Keratitis Diseases 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- ZCYVEMRRCGMTRW-AHCXROLUSA-N Iodine-123 Chemical compound [123I] ZCYVEMRRCGMTRW-AHCXROLUSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 101500014379 Lymnaea stagnalis Ovulation hormone Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 229930045534 Me ester-Cyclohexaneundecanoic acid Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- JMOXSQYGVIXBBZ-UHFFFAOYSA-N N,N-dimethyl-beta-alanine Chemical compound CN(C)CCC(O)=O JMOXSQYGVIXBBZ-UHFFFAOYSA-N 0.000 description 1
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 1
- AVYVHIKSFXVDBG-UHFFFAOYSA-N N-benzyl-N-hydroxy-2,2-dimethylbutanamide Chemical compound C(C1=CC=CC=C1)N(C(C(CC)(C)C)=O)O AVYVHIKSFXVDBG-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical group 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- JZSVOSHKJDKLIQ-NRFANRHFSA-N OCCN[C@@H]1C=2C=CC=C(C=2CCC1)C1=NN=C(S1)C=1C=CC(=C(C#N)C=1)OC(C)C Chemical compound OCCN[C@@H]1C=2C=CC=C(C=2CCC1)C1=NN=C(S1)C=1C=CC(=C(C#N)C=1)OC(C)C JZSVOSHKJDKLIQ-NRFANRHFSA-N 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 102000042822 P family Human genes 0.000 description 1
- 108091082789 P family Proteins 0.000 description 1
- 101150003085 Pdcl gene Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 102100025750 Sphingosine 1-phosphate receptor 1 Human genes 0.000 description 1
- 102100025749 Sphingosine 1-phosphate receptor 2 Human genes 0.000 description 1
- 101710155462 Sphingosine 1-phosphate receptor 2 Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000027522 Sydenham chorea Diseases 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- CPNJYUJMJOGAMA-CQSZACIVSA-N [(1r)-4-bromo-2,3-dihydro-1h-inden-1-yl]oxy-tert-butyl-dimethylsilane Chemical compound C1=CC=C(Br)C2=C1[C@H](O[Si](C)(C)C(C)(C)C)CC2 CPNJYUJMJOGAMA-CQSZACIVSA-N 0.000 description 1
- DRBWRJPFNOBNIO-KOLCDFICSA-N [(2r)-1-[(2r)-2-(pyridine-4-carbonylamino)propanoyl]pyrrolidin-2-yl]boronic acid Chemical compound N([C@H](C)C(=O)N1[C@@H](CCC1)B(O)O)C(=O)C1=CC=NC=C1 DRBWRJPFNOBNIO-KOLCDFICSA-N 0.000 description 1
- PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 1
- JVYPTIPJNJNKBF-UHFFFAOYSA-N [C].C1CCC2=CC=CC=C12 Chemical group [C].C1CCC2=CC=CC=C12 JVYPTIPJNJNKBF-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 125000005426 adeninyl group Chemical group N1=C(N=C2N=CNC2=C1N)* 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000005210 alkyl ammonium group Chemical group 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000001194 anti-hemostatic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 150000003974 aralkylamines Chemical class 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- YCOXTKKNXUZSKD-UHFFFAOYSA-N as-o-xylenol Natural products CC1=CC=C(O)C=C1C YCOXTKKNXUZSKD-UHFFFAOYSA-N 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 239000012911 assay medium Substances 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 125000005602 azabenzimidazolyl group Chemical group 0.000 description 1
- GMWFCJXSQQHBPI-UHFFFAOYSA-N azetidin-3-ol Chemical compound OC1CNC1 GMWFCJXSQQHBPI-UHFFFAOYSA-N 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 125000003828 azulenyl group Chemical group 0.000 description 1
- 229960004669 basiliximab Drugs 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 229950004221 besilate Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 150000001607 bioavailable molecules Chemical class 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 125000002529 biphenylenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C12)* 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 1
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- GXNMJCZKUYHNGO-UHFFFAOYSA-N carbamic acid;2,3-dihydro-1h-indene Chemical class NC(O)=O.C1=CC=C2CCCC2=C1 GXNMJCZKUYHNGO-UHFFFAOYSA-N 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 125000005518 carboxamido group Chemical group 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 229940125844 compound 46 Drugs 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 150000001913 cyanates Chemical class 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000004367 cycloalkylaryl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000012351 deprotecting agent Substances 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- OKKJLVBELUTLKV-MICDWDOJSA-N deuteriomethanol Chemical compound [2H]CO OKKJLVBELUTLKV-MICDWDOJSA-N 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 125000005265 dialkylamine group Chemical group 0.000 description 1
- 125000005266 diarylamine group Chemical group 0.000 description 1
- ZFTFAPZRGNKQPU-UHFFFAOYSA-N dicarbonic acid Chemical compound OC(=O)OC(O)=O ZFTFAPZRGNKQPU-UHFFFAOYSA-N 0.000 description 1
- 229940120124 dichloroacetate Drugs 0.000 description 1
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- 235000019961 diglycerides of fatty acid Nutrition 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- ODCCJTMPMUFERV-UHFFFAOYSA-N ditert-butyl carbonate Chemical compound CC(C)(C)OC(=O)OC(C)(C)C ODCCJTMPMUFERV-UHFFFAOYSA-N 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229950008913 edisilate Drugs 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 230000009762 endothelial cell differentiation Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- BJXYHBKEQFQVES-NWDGAFQWSA-N enpatoran Chemical compound N[C@H]1CN(C[C@H](C1)C(F)(F)F)C1=C2C=CC=NC2=C(C=C1)C#N BJXYHBKEQFQVES-NWDGAFQWSA-N 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- DWCZKKQRUBQFIB-UHFFFAOYSA-N ethyl 2-chlorosulfonylacetate Chemical compound CCOC(=O)CS(Cl)(=O)=O DWCZKKQRUBQFIB-UHFFFAOYSA-N 0.000 description 1
- GWNFQAKCJYEJEW-UHFFFAOYSA-N ethyl 3-[8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanoylamino]benzoate Chemical compound CCOC(=O)C1=CC(NC(=O)CCCCCCCSC2=NN=C(CC3=NN(C)C(=O)C4=CC=CC=C34)N2C)=CC=C1 GWNFQAKCJYEJEW-UHFFFAOYSA-N 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- HQVFCQRVQFYGRJ-UHFFFAOYSA-N formic acid;hydrate Chemical compound O.OC=O HQVFCQRVQFYGRJ-UHFFFAOYSA-N 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229960004275 glycolic acid Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000005252 haloacyl group Chemical group 0.000 description 1
- 125000002192 heptalenyl group Chemical group 0.000 description 1
- 201000010884 herpes simplex virus keratitis Diseases 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- BRWIZMBXBAOCCF-UHFFFAOYSA-N hydrazinecarbothioamide Chemical compound NNC(N)=S BRWIZMBXBAOCCF-UHFFFAOYSA-N 0.000 description 1
- XPXMKIXDFWLRAA-UHFFFAOYSA-N hydrazinide Chemical compound [NH-]N XPXMKIXDFWLRAA-UHFFFAOYSA-N 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 150000002443 hydroxylamines Chemical group 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000003427 indacenyl group Chemical group 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910003480 inorganic solid Inorganic materials 0.000 description 1
- 208000037817 intestinal injury Diseases 0.000 description 1
- 230000003903 intestinal lesions Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007915 intraurethral administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- SNHMUERNLJLMHN-UHFFFAOYSA-N iodobenzene Chemical compound IC1=CC=CC=C1 SNHMUERNLJLMHN-UHFFFAOYSA-N 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- GJRQTCIYDGXPES-UHFFFAOYSA-N iso-butyl acetate Natural products CC(C)COC(C)=O GJRQTCIYDGXPES-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- FGKJLKRYENPLQH-UHFFFAOYSA-M isocaproate Chemical compound CC(C)CCC([O-])=O FGKJLKRYENPLQH-UHFFFAOYSA-M 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- OQAGVSWESNCJJT-UHFFFAOYSA-N isovaleric acid methyl ester Natural products COC(=O)CC(C)C OQAGVSWESNCJJT-UHFFFAOYSA-N 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-M lactobionate Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-M 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000005073 lymphatic endothelial cell Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N monofluoromethane Natural products FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 235000019960 monoglycerides of fatty acid Nutrition 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 1
- UOGRGIANUVKQMW-OAQYLSRUSA-N n-[(1r)-4-[2-(3-cyano-4-propan-2-yloxyphenyl)-1,3-thiazol-5-yl]-2,3-dihydro-1h-inden-1-yl]-2-hydroxyethanesulfonamide Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NC=C(C=2C=3CC[C@H](C=3C=CC=2)NS(=O)(=O)CCO)S1 UOGRGIANUVKQMW-OAQYLSRUSA-N 0.000 description 1
- XDGZRWYSBWHYLN-XMMPIXPASA-N n-[(1r)-4-[2-(3-cyano-4-propan-2-yloxyphenyl)-1,3-thiazol-5-yl]-2,3-dihydro-1h-inden-1-yl]-2-morpholin-4-yl-2-oxoethanesulfonamide Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NC=C(C=2C=3CC[C@H](C=3C=CC=2)NS(=O)(=O)CC(=O)N2CCOCC2)S1 XDGZRWYSBWHYLN-XMMPIXPASA-N 0.000 description 1
- OBSVKRORSAZREK-HXUWFJFHSA-N n-[(1r)-4-[2-(3-cyano-4-propan-2-yloxyphenyl)-1,3-thiazol-5-yl]-2,3-dihydro-1h-inden-1-yl]methanesulfonamide Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NC=C(C=2C=3CC[C@H](C=3C=CC=2)NS(C)(=O)=O)S1 OBSVKRORSAZREK-HXUWFJFHSA-N 0.000 description 1
- XJIVSIIVZGRQGT-HXUWFJFHSA-N n-[(1r)-4-[5-(3-cyano-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-2,3-dihydro-1h-inden-1-yl]acetamide Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NN=C(C=2C=3CC[C@H](C=3C=CC=2)NC(C)=O)S1 XJIVSIIVZGRQGT-HXUWFJFHSA-N 0.000 description 1
- XIKKWMLWIBGUQQ-LJQANCHMSA-N n-[(1r)-4-[5-(3-cyano-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-2,3-dihydro-1h-inden-1-yl]methanesulfonamide Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NN=C(C=2C=3CC[C@H](C=3C=CC=2)NS(C)(=O)=O)S1 XIKKWMLWIBGUQQ-LJQANCHMSA-N 0.000 description 1
- WZNKPBZEBXRJQP-SJKOYZFVSA-N n-[(1r)-4-bromo-2,3-dihydro-1h-inden-1-yl]-2-methylpropane-2-sulfinamide Chemical compound C1=CC=C(Br)C2=C1[C@H](N[S@](=O)C(C)(C)C)CC2 WZNKPBZEBXRJQP-SJKOYZFVSA-N 0.000 description 1
- GQNYXCUMMLMYTG-FQEVSTJZSA-N n-[(1s)-4-[2-(3-cyano-4-propan-2-yloxyphenyl)-1,3-thiazol-5-yl]-2,3-dihydro-1h-inden-1-yl]-2-hydroxyacetamide Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NC=C(C=2C=3CC[C@@H](C=3C=CC=2)NC(=O)CO)S1 GQNYXCUMMLMYTG-FQEVSTJZSA-N 0.000 description 1
- ZPSDPRLOJZUHFX-NRFANRHFSA-N n-[(1s)-4-[2-(3-cyano-4-propan-2-yloxyphenyl)-1,3-thiazol-5-yl]-2,3-dihydro-1h-inden-1-yl]ethanesulfonamide Chemical compound C([C@@H]1NS(=O)(=O)CC)CC2=C1C=CC=C2C(S1)=CN=C1C1=CC=C(OC(C)C)C(C#N)=C1 ZPSDPRLOJZUHFX-NRFANRHFSA-N 0.000 description 1
- CXUCCROTKDGWTC-NRFANRHFSA-N n-[(1s)-4-[2-(3-cyano-4-propan-2-yloxyphenyl)-1,3-thiazol-5-yl]-2,3-dihydro-1h-inden-1-yl]ethenesulfonamide Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NC=C(C=2C=3CC[C@@H](C=3C=CC=2)NS(=O)(=O)C=C)S1 CXUCCROTKDGWTC-NRFANRHFSA-N 0.000 description 1
- OBSVKRORSAZREK-FQEVSTJZSA-N n-[(1s)-4-[2-(3-cyano-4-propan-2-yloxyphenyl)-1,3-thiazol-5-yl]-2,3-dihydro-1h-inden-1-yl]methanesulfonamide Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NC=C(C=2C=3CC[C@@H](C=3C=CC=2)NS(C)(=O)=O)S1 OBSVKRORSAZREK-FQEVSTJZSA-N 0.000 description 1
- OOGFKXCTRSASQJ-FQEVSTJZSA-N n-[(1s)-4-[5-(3-cyano-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-2,3-dihydro-1h-inden-1-yl]-2-hydroxyethanesulfonamide Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NN=C(C=2C=3CC[C@@H](C=3C=CC=2)NS(=O)(=O)CCO)S1 OOGFKXCTRSASQJ-FQEVSTJZSA-N 0.000 description 1
- XJIVSIIVZGRQGT-FQEVSTJZSA-N n-[(1s)-4-[5-(3-cyano-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-2,3-dihydro-1h-inden-1-yl]acetamide Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NN=C(C=2C=3CC[C@@H](C=3C=CC=2)NC(C)=O)S1 XJIVSIIVZGRQGT-FQEVSTJZSA-N 0.000 description 1
- NKUZPUULGAADPC-NRFANRHFSA-N n-[(1s)-5-[5-(3-cyano-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-1,2,3,4-tetrahydronaphthalen-1-yl]-2-hydroxyethanesulfonamide Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NN=C(C=2C=3CCC[C@@H](C=3C=CC=2)NS(=O)(=O)CCO)S1 NKUZPUULGAADPC-NRFANRHFSA-N 0.000 description 1
- LPOIGVZLNWEGJG-UHFFFAOYSA-N n-benzyl-5-(4-methylpiperazin-1-yl)-2-nitroaniline Chemical compound C1CN(C)CCN1C1=CC=C([N+]([O-])=O)C(NCC=2C=CC=CC=2)=C1 LPOIGVZLNWEGJG-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229950005216 napadisilate Drugs 0.000 description 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 229940054534 ophthalmic solution Drugs 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000008184 oral solid dosage form Substances 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 230000002746 orthostatic effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- 238000005897 peptide coupling reaction Methods 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical class OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- KYKNRZGSIGMXFH-ZVGUSBNCSA-M potassium bitartrate Chemical compound [K+].OC(=O)[C@H](O)[C@@H](O)C([O-])=O KYKNRZGSIGMXFH-ZVGUSBNCSA-M 0.000 description 1
- 239000001472 potassium tartrate Substances 0.000 description 1
- 229940111695 potassium tartrate Drugs 0.000 description 1
- 235000011005 potassium tartrates Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000000039 preparative column chromatography Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- OGHBATFHNDZKSO-UHFFFAOYSA-N propan-2-olate Chemical compound CC(C)[O-] OGHBATFHNDZKSO-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229940090181 propyl acetate Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- 239000003909 protein kinase inhibitor Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000001725 pyrenyl group Chemical group 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 1
- 125000004941 pyridazin-5-yl group Chemical group N1=NC=CC(=C1)* 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- HDOUGSFASVGDCS-UHFFFAOYSA-N pyridin-3-ylmethanamine Chemical compound NCC1=CC=CN=C1 HDOUGSFASVGDCS-UHFFFAOYSA-N 0.000 description 1
- QJZUKDFHGGYHMC-UHFFFAOYSA-N pyridine-3-carbaldehyde Chemical compound O=CC1=CC=CN=C1 QJZUKDFHGGYHMC-UHFFFAOYSA-N 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- LCDCPQHFCOBUEF-UHFFFAOYSA-N pyrrolidine-1-carboxamide Chemical compound NC(=O)N1CCCC1 LCDCPQHFCOBUEF-UHFFFAOYSA-N 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 229910052705 radium Inorganic materials 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229910052701 rubidium Inorganic materials 0.000 description 1
- YAYGSLOSTXKUBW-UHFFFAOYSA-N ruthenium(2+) Chemical compound [Ru+2] YAYGSLOSTXKUBW-UHFFFAOYSA-N 0.000 description 1
- 101150024819 s1pr1 gene Proteins 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 150000003385 sodium Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 1
- 229960002218 sodium chlorite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 1
- 125000001174 sulfone group Chemical group 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 125000003375 sulfoxide group Chemical group 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- QCIWZIYBBNEPKB-UHFFFAOYSA-N tert-butyl(dimethyl)silane Chemical compound C[SiH](C)C(C)(C)C QCIWZIYBBNEPKB-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 150000005621 tetraalkylammonium salts Chemical class 0.000 description 1
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 1
- 125000001935 tetracenyl group Chemical group C1(=CC=CC2=CC3=CC4=CC=CC=C4C=C3C=C12)* 0.000 description 1
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 150000004867 thiadiazoles Chemical group 0.000 description 1
- 125000000101 thioether group Chemical group 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- JMXKSZRRTHPKDL-UHFFFAOYSA-N titanium ethoxide Chemical compound [Ti+4].CC[O-].CC[O-].CC[O-].CC[O-] JMXKSZRRTHPKDL-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000440 toxicity profile Toxicity 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 125000005259 triarylamine group Chemical group 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- SZYJELPVAFJOGJ-UHFFFAOYSA-N trimethylamine hydrochloride Chemical compound Cl.CN(C)C SZYJELPVAFJOGJ-UHFFFAOYSA-N 0.000 description 1
- NRZWQKGABZFFKE-UHFFFAOYSA-N trimethylsulfonium Chemical compound C[S+](C)C NRZWQKGABZFFKE-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 229940075466 undecylenate Drugs 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
- 229950000339 xinafoate Drugs 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161486184P | 2011-05-13 | 2011-05-13 | |
| PCT/US2012/037609 WO2012158550A2 (en) | 2011-05-13 | 2012-05-11 | Selective heterocyclic sphingosine 1 phosphate receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2758841T3 true ES2758841T3 (es) | 2020-05-06 |
Family
ID=47177578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12785231T Active ES2758841T3 (es) | 2011-05-13 | 2012-05-11 | Moduladores heterocíclicos selectivos del receptor de la esfingosina-1-fosfato |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9481659B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2706999B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6129159B2 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2758841T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012158550A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY161854A (en) | 2009-11-13 | 2017-05-15 | Receptos Inc | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis |
| US9115054B2 (en) | 2013-02-21 | 2015-08-25 | Bristol-Myers Squibb Company | Tetrahydronaphthalenyl compounds useful as sipi agonists |
| CN106187945A (zh) * | 2016-07-22 | 2016-12-07 | 辽宁师范大学 | 一种有机合成中间体的合成方法 |
| BR112019001153A2 (pt) | 2016-07-22 | 2019-04-30 | Shijiazhuang Sagacity New Drug Development Co., Ltd. | agonista s1p1 e aplicação do mesmo |
| US10981900B2 (en) * | 2017-02-28 | 2021-04-20 | Medshine Discovery Inc. | Spiro compound and use thereof |
| US20210340115A1 (en) * | 2018-09-12 | 2021-11-04 | Pharmazell Gmbh | A PROCESS FOR THE PREPARATION OF OZANIMOD AND ITS INTERMEDIATE (S)-l-AMINO-2,3-DIHYDRO-1H-INDENE-4-CARBONITRILE |
| CN112457305B (zh) | 2019-09-09 | 2025-01-10 | 上海长森药业有限公司 | 含三环结构的芳香杂环化合物，及其制备方法和应用 |
| EP4116294B1 (en) * | 2020-03-04 | 2025-09-03 | Helioeast Pharmaceutical Co., Ltd. | Benzo 2-azaspiro[4.4]nonane compound and use thereof |
| JP7720099B2 (ja) | 2020-05-11 | 2025-08-07 | シャンハイ ロングウッド バイオファルマシューティカルズ カンパニー リミテッド | 免疫調節剤としてのビアリール環結合芳香族複素環誘導体の調製およびその適用 |
| JP7738667B2 (ja) * | 2021-04-09 | 2025-09-12 | ヒーリオイースト ファーマシューティカル カンパニー リミテッド | オキサジアゾール置換スピロ環系化合物とその使用 |
| CN117164415B (zh) * | 2023-07-24 | 2024-08-02 | 湖北航天化学技术研究所 | 一种硼酸酯型含氟燃烧促进剂及其制备方法和应用 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1479544A (en) | 1974-02-07 | 1977-07-13 | American Cyanamid Co | 1,2,3,4-tetrahydro-1-naphthylurea derivatives their preparation and their use |
| FR2628103B1 (fr) | 1988-03-03 | 1991-06-14 | Roussel Uclaf | Nouveaux esters pyrethrinoides portant un noyau indanyle, leur procede de preparation et leur application comme pesticides |
| US5039802A (en) * | 1990-04-18 | 1991-08-13 | Merck & Co., Inc. | Arylation process for preparation of chiral catalysts for ketone reduction |
| AU1886892A (en) | 1991-04-12 | 1992-11-17 | Schering Corporation | Bicyclic amides as inhibitors of acyl-coenzyme a: cholesterol acyl transferase |
| GB2290790A (en) * | 1994-06-30 | 1996-01-10 | Merck & Co Inc | Asymmetric synthesis of 6-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes |
| NZ505599A (en) | 1998-01-23 | 2003-06-30 | Sankyo Co | Morpholino alkyl substituted spiropiperidine derivatives useful as tachykinin receptor antagonists |
| US20040058894A1 (en) | 2002-01-18 | 2004-03-25 | Doherty George A. | Selective S1P1/Edg1 receptor agonists |
| CA2509218C (en) | 2002-12-20 | 2010-09-07 | Merck & Co., Inc. | 1-(amino)indanes and (1,2-dihydro-3-amino)-benzofurans, benzothiophenes and indoles as edg receptor agonists |
| EP3889142B1 (en) | 2003-04-11 | 2022-06-15 | PTC Therapeutics, Inc. | 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease |
| BRPI0409627A (pt) * | 2003-04-21 | 2006-04-25 | Elan Pharm Inc | 2-hidróxi-3-diaminoalcanos de fenacila |
| JP2007528872A (ja) | 2003-10-01 | 2007-10-18 | メルク エンド カムパニー インコーポレーテッド | Ｓ１ｐ受容体アゴニストとしての３，５−アリール置換、ヘテロアリール置換またはシクロアルキル置換された１，２，４−オキサジアゾール化合物 |
| CA2547198A1 (en) * | 2003-12-17 | 2005-06-30 | Merck & Co., Inc. | (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists |
| US7585881B2 (en) | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| US20060173183A1 (en) | 2004-12-31 | 2006-08-03 | Alantos Pharmaceuticals, Inc., | Multicyclic bis-amide MMP inhibitors |
| CA2600008A1 (en) | 2005-02-22 | 2006-11-16 | Teva Pharmaceutical Industries Ltd. | Improved process for the synthesis of enantiomeric indanylamine derivatives |
| KR100667075B1 (ko) | 2005-07-22 | 2007-01-10 | 삼성에스디아이 주식회사 | 주사 구동부 및 이를 포함하는 유기 전계발광 표시장치 |
| EP1924546A1 (en) * | 2005-09-14 | 2008-05-28 | Amgen, Inc | Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders |
| EP1963509A4 (en) | 2005-12-21 | 2009-07-29 | Joseph Gabriele | CATECHOLAMINE-REGULATED PROTEIN |
| EP2007749A2 (en) | 2006-03-13 | 2008-12-31 | Pfizer Products Inc. | Tetralines antagonists of the h-3 receptor |
| US20080009534A1 (en) | 2006-07-07 | 2008-01-10 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
| CA2669104A1 (en) | 2006-11-21 | 2008-05-29 | University Of Virginia Patent Foundation | Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity |
| KR20090095648A (ko) | 2006-12-15 | 2009-09-09 | 아보트 러보러터리즈 | 신규한 옥사디아졸 화합물 |
| CA2671943A1 (en) * | 2006-12-21 | 2008-07-17 | Pfizer Products Inc. | Compounds having both angiotensin ii receptor antagonism and ppary activating activities |
| JO2701B1 (en) | 2006-12-21 | 2013-03-03 | جلاكسو جروب ليميتد | Vehicles |
| WO2008106204A1 (en) | 2007-02-28 | 2008-09-04 | Rib-X-Pharmaceuticals, Inc. | Macrolide compounds and methods of making and using the same |
| WO2009048474A1 (en) * | 2007-10-12 | 2009-04-16 | Pharmacopeia, Inc. | 2,7,9-substituted purinone derivatives for immunosuppression |
| US20090298894A1 (en) | 2008-04-21 | 2009-12-03 | Asahi Kasei Pharma Corporation | Amino acid compounds |
| MY156381A (en) | 2008-05-14 | 2016-02-15 | Scripps Research Inst | Novel modulators of sphingosine phosphate receptors |
| US20100249071A1 (en) * | 2009-03-30 | 2010-09-30 | Exelixis, Inc. | Modulators of S1P and Methods of Making And Using |
| GB0910674D0 (en) * | 2009-06-19 | 2009-08-05 | Glaxo Group Ltd | Novel compounds |
| GB0910691D0 (en) * | 2009-06-19 | 2009-08-05 | Glaxo Group Ltd | Novel compounds |
| WO2011005290A1 (en) | 2009-06-23 | 2011-01-13 | Arena Pharmaceuticals, Inc. | Disubstituted oxadiazole derivatives useful in the treatment of autoimmune and inflammatory disorders |
| GB0911130D0 (en) * | 2009-06-26 | 2009-08-12 | Glaxo Group Ltd | Novel compounds |
| RS57070B1 (sr) | 2009-11-13 | 2018-06-29 | Celgene Int Ii Sarl | Modulatori sfingozin 1 fosfatnog receptora i postupci asimetričnih sinteza |
| EA025672B1 (ru) * | 2009-11-13 | 2017-01-30 | Рецептос Ллк | Селективные гетероциклические модуляторы рецептора сфингозин-1-фосфата |
| MY161854A (en) | 2009-11-13 | 2017-05-15 | Receptos Inc | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis |
| CN106344576A (zh) | 2011-10-12 | 2017-01-25 | 泰华制药工业有限公司 | 以拉喹莫德和芬戈莫德的组合治疗多发性硬化症 |
-
2012
- 2012-05-11 ES ES12785231T patent/ES2758841T3/es active Active
- 2012-05-11 WO PCT/US2012/037609 patent/WO2012158550A2/en not_active Ceased
- 2012-05-11 JP JP2014510511A patent/JP6129159B2/ja active Active
- 2012-05-11 US US14/117,514 patent/US9481659B2/en active Active
- 2012-05-11 EP EP12785231.7A patent/EP2706999B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP6129159B2 (ja) | 2017-05-17 |
| EP2706999A4 (en) | 2015-07-15 |
| EP2706999A2 (en) | 2014-03-19 |
| JP2014517836A (ja) | 2014-07-24 |
| EP2706999B1 (en) | 2019-08-28 |
| US9481659B2 (en) | 2016-11-01 |
| WO2012158550A9 (en) | 2017-10-26 |
| US20150299179A1 (en) | 2015-10-22 |
| WO2012158550A3 (en) | 2014-05-01 |
| WO2012158550A2 (en) | 2012-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2758841T3 (es) | Moduladores heterocíclicos selectivos del receptor de la esfingosina-1-fosfato | |
| ES2858337T3 (es) | Moduladores selectivos del receptor de fosfato de esfingosina 1 y métodos de síntesis quiral | |
| EP2498609B1 (en) | Selective heterocyclic sphingosine 1 phosphate receptor modulators | |
| AU2010320041B2 (en) | Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis | |
| WO2015066515A1 (en) | Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith | |
| AU2015202660A1 (en) | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis | |
| HK1175652A (en) | Selective heterocyclic sphingosine 1 phosphate receptor modulators | |
| HK1175652B (en) | Selective heterocyclic sphingosine 1 phosphate receptor modulators |